{"protocolSection":{"identificationModule":{"nctId":"NCT03999996","orgStudyIdInfo":{"id":"DEN-303"},"secondaryIdInfos":[{"id":"2023-000027-36","type":"EUDRACT_NUMBER"},{"id":"2023","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2023"}],"organization":{"fullName":"Takeda","class":"INDUSTRY"},"briefTitle":"Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose","officialTitle":"A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue"},"statusModule":{"statusVerifiedDate":"2026-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-11-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-05-25","type":"ACTUAL"},"completionDateStruct":{"date":"2024-05-25","type":"ACTUAL"},"studyFirstSubmitDate":"2019-06-25","studyFirstSubmitQcDate":"2019-06-25","studyFirstPostDateStruct":{"date":"2019-06-27","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-05-23","resultsFirstSubmitQcDate":"2025-05-23","resultsFirstPostDateStruct":{"date":"2025-06-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-07-02","lastUpdatePostDateStruct":{"date":"2026-07-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Takeda","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315 (NCT03341637) (Mexico) and for up to 36 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-304 (NCT03423173) (United States \\[US\\]) and to describe the impact of a tetravalent dengue vaccine (TDV) booster dose vs placebo on antibody response for each of the 4 dengue serotypes at 1 month and 6 months post administration of the TDV booster or placebo.","detailedDescription":"The vaccine tested in this study is Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV). This study will look at the long-term antibody persistence and safety of Takeda's TDV in healthy adolescents and adults and will assess the impact of a booster dose.\n\nThe study has enrolled 365 healthy participants. Participants who previously received TDV in two parent trials (DEN-304 \\[NCT03423173\\] and DEN-315 \\[NCT03341637\\]), will be invited to participate in this follow-up trial. Participants will be assessed for antibody persistence and safety from Baseline (Month 0) through Month 15 (for participants from parent trial DEN-304 \\[US\\]) or Month 42 (for participants from parent trial DEN-315 \\[Mexico\\]). At Month 15 (for participants from parent trial DEN-304 \\[US\\]) or at Month 42 (for participants from parent trial DEN-315 \\[Mexico\\]), eligible participants will be randomized in 1:1 ratio to one of two trial groups to receive TDV or placebo:\n\nA. Group 1- TDV 0.5 mL subcutaneous (SC) injection at Month 15 for participants from parent trial DEN-304 (US) or at Month 42 for participants from parent trial DEN-315 (Mexico\\]).\n\nB. Group 2- Takeda's tetravalent dengue placebo (dummy SC injection - this is a liquid that looks like the study drug but has no active ingredient), 0.5 mL, subcutaneous injection at Month 15 for participants from parent trial DEN-304 (US) or at Month 42 for participants from parent trial DEN-315 (Mexico).\n\nThis multi-centre trial will be conducted in US and Mexico. The overall time to participate in this study is up to 21 months for parent trial DEN-304 (US) and up to 48 months for parent trial DEN-315 (Mexico). Participants from parent trial DEN-304 (US) and participants from parent trial DEN-315 (Mexico) will come for 5 visits to the clinic which includes a final visit (Visit 5) 6 months after the booster dose for a follow-up assessment."},"conditionsModule":{"conditions":["Dengue Fever"],"keywords":["Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"The study will be double-blinded, randomized, and placebo-controlled from Month 15 onwards for participants from parent trial DEN-304 (US) and from Month 42 onwards for participants from parent trial DEN-315 (Mexico).","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":365,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Prior to Booster: DEN-304","type":"EXPERIMENTAL","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Month 15.","interventionNames":["Biological: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)"]},{"label":"Prior to Booster: DEN-315","type":"EXPERIMENTAL","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Month 42.","interventionNames":["Biological: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)"]},{"label":"Booster Phase: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received TDV placebo-matching 0.5 milliliters (ml) injection, subcutaneous (SC), once at Month 15 for participants from parent trial DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).","interventionNames":["Biological: Placebo"]},{"label":"Booster Phase: TDV","type":"EXPERIMENTAL","description":"Participants received TDV 0.5 ml, injection, SC, once at Month 15 for participants from parent trial DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).","interventionNames":["Biological: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)"]}],"interventions":[{"type":"BIOLOGICAL","name":"Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)","description":"TDV subcutaneous injection","armGroupLabels":["Booster Phase: TDV","Prior to Booster: DEN-304","Prior to Booster: DEN-315"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Normal Saline (0.9% NaCl) subcutaneous injection","armGroupLabels":["Booster Phase: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","description":"GMTs of neutralizing antibodies were measured by microneutralization test 50% (MNT50) for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 0 (Day 1)"},{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 12"},{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","timeFrame":"Month 15 (DEN-304)"},{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 3 at Month 42 for participants from parent trial DEN-315.","timeFrame":"Month 42 (DEN-315)"},{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 1 (Month 0 [Day 1])","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 0 [Day 1)"},{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 2 (Month 12)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 12"},{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","timeFrame":"Month 15 (DEN-304)"},{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 3 at Month 42 for participants from parent trial DEN-315.","timeFrame":"Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 0 (Day 1)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 12"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity Rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","timeFrame":"Month 15 (DEN-304)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","timeFrame":"Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 1 [Month 0 (Day 1])","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 0 (Day 1)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 2 (Month 12)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 12"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","timeFrame":"Month 15 (DEN-304)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) ((DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","timeFrame":"Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 0 (Day 1)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 12"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for parent trial DEN-304.","timeFrame":"Month 15 (DEN-304)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","timeFrame":"Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 1 (Month 0 [Day 1])","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 0 (Day 1)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 2 (Month 12)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for both parent trials (DEN-304 and DEN-315).","timeFrame":"Month 12"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. (DEN-304). All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for parent trial DEN-304.","timeFrame":"Month 15 (DEN-304)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","timeFrame":"Month 42 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 5, 6 months post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 16) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 21) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 42 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 43) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 48) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","timeFrame":"6 months post-booster dose at Month 48 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 16) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 21) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 42 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 43) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)"},{"measure":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 48) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","timeFrame":"6 months post-booster dose at Month 48 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","timeFrame":"6 months post-booster dose at Month 48 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)"},{"measure":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","timeFrame":"6 months post-booster dose at Month 48 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose at Visit 3 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose at Visit 5 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","timeFrame":"1 month post-booster dose at Month 16 (DEN-304.)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 1 Month Post-Booster Dose at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-booster Dose at 6 Months Post-Booster Dose at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","timeFrame":"6 months post-Booster dose at Month 48 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\ any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\ any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\ any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 15 (DEN-304)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","timeFrame":"Pre-booster dose at Month 42 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)"},{"measure":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-booster Dose at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","timeFrame":"6 months post-Booster dose at Month 48 (DEN-315)"}],"secondaryOutcomes":[{"measure":"Geometric Mean Ratio (GMR) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes for All Participants Prior to the Booster Dose","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","timeFrame":"Month 12 vs Month 0, Month 15 (DEN-304) vs parent trial Month 4, Mont 42 (DEN315) vs parent trial Month 4, Month 0 vs parent trial Month 9, Month 12 vs parent trial Month 9"},{"measure":"Geometric Mean Ratio (GMR) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes by Serostatus at Baseline in the Parent Trials Prior to the Booster Dose","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial.","timeFrame":"Month 12 vs Month 0, Month 15 (DEN-304) vs parent trial Month 4, Month 42 (DEN315) vs parent trial Month 4, Month 0 vs parent trial Month 9, Month 12 vs parent trial Month 9"},{"measure":"GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Booster Phase","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","timeFrame":"Months (M) 1&6 post-booster dose in current trial vs M 4 in parent trials; post-booster M 6 vs post-booster M 1; post-booster M 1 vs pre-booster (M 15 for DEN-304/M 42 for DEN-315); post-booster M 6 vs pre-booster (M 15 for DEN-304/M 42 for DEN-315)"},{"measure":"GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes by Serostatus at Baseline in the Parent Trials in the Booster Phase","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial.","timeFrame":"Months (M) 1&6 post-booster dose in current trial vs M 4 in parent trials; post-booster M 1 vs pre-booster (M 15 for DEN-304/M 42 for DEN-315); post-booster M 6 vs pre-booster (M 15 for DEN-304/M 42 for DEN-315); post-booster M 6 vs post-booster M 1"},{"measure":"Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Within 7 Days Post-Booster Vaccination","description":"Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days post-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315). AEs were graded by the investigator in the following manner: Mild: Grade 1: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with everyday activities. Relieved with or without symptomatic treatment; Moderate: Grade 2: Sufficient discomfort is present to cause interference with normal activity. Only partially relieved with symptomatic treatment; Severe: Grade 3: Extreme distress, causing significant impairment of functioning or incapacitation. Prevents normal everyday activities. Not relieved with symptomatic treatment.","timeFrame":"Days 1 through 7 post-booster dose at Visit 3 (Month 15 [DEN-304]) and (Month 42 [DEN-315])"},{"measure":"Percentage of Participants With Solicited Systemic Adverse Events Within 14 Days Post-Booster Vaccination by Severity","description":"Solicited systemic AEs are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days post-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315). AEs were graded by the investigator in the following manner: Mild: Grade 1: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with everyday activities. Relieved with or without symptomatic treatment; Moderate: Grade 2: Sufficient discomfort is present to cause interference with normal activity. Only partially relieved with symptomatic treatment; Severe: Grade 3: Extreme distress, causing significant impairment of functioning or incapacitation. Prevents normal everyday activities. Not relieved with symptomatic treatment.","timeFrame":"Days 1 through 14 post-booster dose at Visit 3 (Month 15 [DEN-304]) and (Month 42 [DEN-315])"},{"measure":"Percentage of Participants With Any Unsolicited AEs in the Booster Phase","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine or placebo; it does not necessarily have to have a causal relationship with this treatment.","timeFrame":"Days 1 through 28 post-booster dose at Visit 3 (Month 15 [DEN-304]) and (Month 42 [DEN-315])"},{"measure":"Percentage of Participants With Any Medically Attended AEs (MAAEs) in the Booster Phase","description":"MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.","timeFrame":"Month 15 post-booster dose through Month 21 (DEN-304); Month 42 post-booster dose through Month 48 (DEN-315)"},{"measure":"Percentage of Participants With Any Serious Adverse Events (SAEs) Prior to the Booster Dose","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine or placebo; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important event.","timeFrame":"Month 0 through Month 15 (DEN-304) and Month 42 (DEN-315)"},{"measure":"Percentage of Participants With Any SAEs in the Booster Phase","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine or placebo; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important event.","timeFrame":"Month 15 post-booster dose after vaccination through Month 21 (DEN-304); Month 42 post-booster dose after vaccination through Month 48 (DEN-315)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. Male or female participants (irrespective of serostatus at baseline in the parent trials (DEN-304 \\[(NCT03423173)\\] and DEN-315 \\[NCT03341637\\]) who received at least one dose of Takeda's tetravalent dengue vaccine candidate (TDV) in the parent trials and have data from at least one blood draw post-vaccination.\n\nExclusion Criteria:\n\n1. Participants with a prolonged period of habitation (≥1 year) in a dengue endemic area within the 2 years prior to Visit 1 Day 1 (Month 0).\n2. Previous and planned vaccination (during the trial conduct), against any flavivirus including dengue (other than Takeda's TDV), yellow fever (YF), Japanese encephalitis (JE) viruses or tick-borne encephalitis.\n\nBooster Exclusion Criteria:\n\n1. Participants for whom baseline serostatus is not defined in the parent trials (DEN-304 \\[(NCT03423173)\\] and DEN-315 \\[NCT03341637\\]).\n2. Participants with any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (eg, Guillain-Barré syndrome).\n3. Known or suspected impairment/alteration of immune function, including:\n\n   1. Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Month 42 for participants from parent trial DEN-315 (Mexico)/ Month 15 for participants from parent trial DEN-304 (US); use of inhaled, intranasal, or topical corticosteroids is allowed.\n   2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Month 42 for participants from parent trial DEN-315 (Mexico)/ Month 15 for participants from parent trial DEN-304 (US).\n   3. Administration of immunoglobulins and/or any blood products within the 3 months prior to administration of the TDV booster or placebo at Month 42 for participants from parent trial DEN-315 (Mexico)/ Month 15 for participants from parent trial DEN-304 (US); consider whether applicable as an exclusion criterion or criterion for delay.\n   4. Receipt of immunostimulants within 60 days prior to Month 42 for participants from parent trial DEN-315 (Mexico)/ Month 15 for participants from parent trial DEN-304 (US).\n   5. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Month 42 for participants from parent trial DEN-315 (Mexico) / Month 15 for participants from parent trial DEN-304 (US).\n   6. Known human immunodeficiency virus (HIV) infection or HIV-related disease.\n   7. Hepatitis C virus infection.\n   8. Genetic immunodeficiency.\n4. Abnormalities of splenic or thymic function.\n5. Participants with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.\n6. Participants with history of current or previous infection with a flavivirus such as dengue, Zika, YF, JE, West Nile fever, tick-borne encephalitis or Murray Valley encephalitis and participants with a prolonged period of habitation (≥1 year) in a dengue endemic area during trial conduct.","healthyVolunteers":true,"sex":"ALL","minimumAge":"13 Years","maximumAge":"63 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Takeda","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"AES - DRS - Optimal Research Alabama - Huntsville","city":"Huntsville","state":"Alabama","zip":"35802","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"AES - DRS - Optimal Research Illinois - Peoria","city":"Peoria","state":"Illinois","zip":"61614","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Alliance for Multispecialty Research, LLC - Newton - PPDS","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Optima Research","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"AES - DRS - Synexus Clinical Research US, Inc. Minneapolis","city":"Richfield","state":"Minnesota","zip":"55423-2590","country":"United States","geoPoint":{"lat":44.8833,"lon":-93.283}},{"facility":"AES - DRS - Synexus Clinical Research US, Inc. - St. Louis","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"AES - DRS - Synexus Clinical Research US, Inc. - Omaha","city":"Papillion","state":"Nebraska","zip":"68046","country":"United States","geoPoint":{"lat":41.15444,"lon":-96.04224}},{"facility":"Advanced Clinical Research/Velocity Clinical Research","city":"West Jordan","state":"Utah","zip":"84088-8865","country":"United States","geoPoint":{"lat":40.60967,"lon":-111.9391}},{"facility":"Instituto Nacional de Pediatria","city":"Mexico City","zip":"04530","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"CAIMED Investigacion en Salud S.A de C.V.","city":"Mexico City","zip":"06760","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}}]},"referencesModule":{"references":[{"pmid":"40099800","type":"DERIVED","citation":"Rauscher M, Youard Z, Faccin A, Patel SS, Pang H, Zent O. Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine. Expert Rev Vaccines. 2025 Dec;24(1):221-229. doi: 10.1080/14760584.2025.2480297. Epub 2025 Mar 27."}],"seeAlsoLinks":[{"label":"To obtain more information about this study, click this link.","url":"https://clinicaltrials.takeda.com/study-detail/5f6b603c4db2bf003ab4a33e?idFilter=%5B%22DEN-303%22%5D"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"accessCriteria":"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.","url":"https://vivli.org/ourmember/takeda/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Healthy participants who received Takeda's Dengue Tetravalent Vaccine (TDV) in two parent trials, DEN-304 \\[NCT03423173\\] and DEN-315 \\[NCT03341637\\] were enrolled to receive either placebo or TDV.","recruitmentDetails":"Participants took part in the study at multiple investigative sites in United States (US) and Mexico from 12 November 2019 to 25 May 2024.","groups":[{"id":"FG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"FG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."},{"id":"FG002","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 milliliters (ml) injection, subcutaneous (SC), once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"FG003","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"periods":[{"title":"Prior to Booster","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"246"},{"groupId":"FG001","numSubjects":"119"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"149"},{"groupId":"FG001","numSubjects":"84"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"97"},{"groupId":"FG001","numSubjects":"35"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"22"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal of Consent","reasons":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Reason Not Specified","reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]},{"title":"Booster Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"118"},{"groupId":"FG003","numSubjects":"115"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"115"},{"groupId":"FG003","numSubjects":"110"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Withdrawal of Consent","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Reason Not Specified","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety Set (SAF) included all participants who agreed to participate in the current trial, did not screen fail, and who received at least one dose of Takeda's TDV in the parent trials.","groups":[{"id":"BG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"BG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"246"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"365"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44.4","spread":"11.03"},{"groupId":"BG001","value":"16.3","spread":"1.77"},{"groupId":"BG002","value":"35.2","spread":"16.01"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"145"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"215"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"150"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"127"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"238"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"35"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"201"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"121"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","description":"GMTs of neutralizing antibodies were measured by microneutralization test 50% (MNT50) for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","populationDescription":"Per Protocol Set (PPS) included all participants from the Full Analysis Set (FAS) who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Month 0 (Day 1)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"119"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"76.8","lowerLimit":"62.0","upperLimit":"95.2"},{"groupId":"OG001","value":"88.6","lowerLimit":"70.4","upperLimit":"111.5"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"539.6","lowerLimit":"460.9","upperLimit":"631.7"},{"groupId":"OG001","value":"425.6","lowerLimit":"352.7","upperLimit":"513.5"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"33.7","lowerLimit":"28.0","upperLimit":"40.5"},{"groupId":"OG001","value":"29.5","lowerLimit":"24.1","upperLimit":"36.1"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"40.0","lowerLimit":"33.1","upperLimit":"48.4"},{"groupId":"OG001","value":"27.1","lowerLimit":"21.9","upperLimit":"33.6"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Month 12","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"58.4","lowerLimit":"45.0","upperLimit":"75.7"},{"groupId":"OG001","value":"96.4","lowerLimit":"69.9","upperLimit":"132.7"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"427.3","lowerLimit":"360.2","upperLimit":"507.0"},{"groupId":"OG001","value":"276.1","lowerLimit":"208.3","upperLimit":"365.9"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"32.8","lowerLimit":"26.5","upperLimit":"40.4"},{"groupId":"OG001","value":"25.3","lowerLimit":"18.5","upperLimit":"34.7"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"30.1","lowerLimit":"24.5","upperLimit":"37.1"},{"groupId":"OG001","value":"22.9","lowerLimit":"17.6","upperLimit":"29.8"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"121.7","lowerLimit":"93.3","upperLimit":"158.7"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"560.2","lowerLimit":"473.9","upperLimit":"662.2"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"40.3","lowerLimit":"32.6","upperLimit":"49.8"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"37.6","lowerLimit":"29.9","upperLimit":"47.2"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 3 at Month 42 for participants from parent trial DEN-315.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"106.5","lowerLimit":"80.8","upperLimit":"140.4"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"202.9","lowerLimit":"159.5","upperLimit":"258.2"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"21.9","lowerLimit":"16.8","upperLimit":"28.5"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"12.2","upperLimit":"20.5"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 1 (Month 0 [Day 1])","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Month 0 [Day 1)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"119"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus:Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"122.8","lowerLimit":"59.5","upperLimit":"253.2"},{"groupId":"OG001","value":"259.3","lowerLimit":"135.7","upperLimit":"495.5"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"560.1","lowerLimit":"314.3","upperLimit":"998.1"},{"groupId":"OG001","value":"714.1","lowerLimit":"355.2","upperLimit":"1435.7"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","lowerLimit":"26.1","upperLimit":"88.9"},{"groupId":"OG001","value":"118.7","lowerLimit":"28.3","upperLimit":"497.3"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","lowerLimit":"32.1","upperLimit":"118.2"},{"groupId":"OG001","value":"112.4","lowerLimit":"29.6","upperLimit":"427.5"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","lowerLimit":"57.2","upperLimit":"88.9"},{"groupId":"OG001","value":"82.0","lowerLimit":"64.7","upperLimit":"103.9"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"536.4","lowerLimit":"456.9","upperLimit":"629.6"},{"groupId":"OG001","value":"410.0","lowerLimit":"337.1","upperLimit":"498.6"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","lowerLimit":"26.3","upperLimit":"38.5"},{"groupId":"OG001","value":"26.7","lowerLimit":"22.1","upperLimit":"32.2"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","lowerLimit":"30.7","upperLimit":"45.4"},{"groupId":"OG001","value":"24.5","lowerLimit":"19.9","upperLimit":"30.0"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 2 (Month 12)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Month 12","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus:Positive; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","lowerLimit":"37.2","upperLimit":"204.4"},{"groupId":"OG001","value":"93.5","lowerLimit":"0.0","upperLimit":"6220000"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"544.5","lowerLimit":"279.1","upperLimit":"1062.4"},{"groupId":"OG001","value":"272.6","lowerLimit":"0.0","upperLimit":"12600000"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","lowerLimit":"23.2","upperLimit":"101.6"},{"groupId":"OG001","value":"34.0","lowerLimit":"NA","upperLimit":"NA","comment":"The confidence interval was not estimable due to an observed standard deviation of 0."}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","lowerLimit":"22.2","upperLimit":"104.0"},{"groupId":"OG001","value":"21.5","lowerLimit":"16.0","upperLimit":"28.9"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","lowerLimit":"41.7","upperLimit":"71.9"},{"groupId":"OG001","value":"96.5","lowerLimit":"69.3","upperLimit":"134.2"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"411.1","lowerLimit":"346.6","upperLimit":"487.6"},{"groupId":"OG001","value":"276.2","lowerLimit":"206.7","upperLimit":"369.0"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"24.8","upperLimit":"38.2"},{"groupId":"OG001","value":"25.0","lowerLimit":"18.0","upperLimit":"34.7"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","lowerLimit":"22.7","upperLimit":"34.5"},{"groupId":"OG001","value":"23.0","lowerLimit":"17.5","upperLimit":"30.2"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus:Positive; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"214.3","lowerLimit":"80.6","upperLimit":"569.9"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"484.5","lowerLimit":"263.4","upperLimit":"891.3"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","lowerLimit":"29.9","upperLimit":"122.1"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","lowerLimit":"26.4","upperLimit":"129.6"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110.9","lowerLimit":"84.9","upperLimit":"145.0"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"573.6","lowerLimit":"483.5","upperLimit":"680.4"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","lowerLimit":"30.3","upperLimit":"46.9"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","lowerLimit":"27.7","upperLimit":"44.1"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 3 at Month 42 for participants from parent trial DEN-315.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus:Positive; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"320.0","lowerLimit":"119.6","upperLimit":"856.4"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"436.6","lowerLimit":"156.3","upperLimit":"1219.1"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","lowerLimit":"17.5","upperLimit":"369.3"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","lowerLimit":"5.0","upperLimit":"242.6"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","lowerLimit":"72.2","upperLimit":"127.2"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"188.6","lowerLimit":"147.3","upperLimit":"241.4"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","lowerLimit":"15.1","upperLimit":"24.8"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"11.5","upperLimit":"18.7"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 0 (Day 1)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"119"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"85.8","lowerLimit":"80.7","upperLimit":"89.9"},{"groupId":"OG001","value":"92.4","lowerLimit":"86.1","upperLimit":"96.5"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"98.7","lowerLimit":"96.4","upperLimit":"99.7"},{"groupId":"OG001","value":"99.2","lowerLimit":"95.4","upperLimit":"100"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"72.4","lowerLimit":"66.3","upperLimit":"78.0"},{"groupId":"OG001","value":"79.8","lowerLimit":"71.5","upperLimit":"86.6"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"80.8","lowerLimit":"75.2","upperLimit":"85.6"},{"groupId":"OG001","value":"76.5","lowerLimit":"67.8","upperLimit":"83.8"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 12","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"78.6","lowerLimit":"71.9","upperLimit":"84.3"},{"groupId":"OG001","value":"97.9","lowerLimit":"88.9","upperLimit":"100"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98.0","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"92.6","upperLimit":"100"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"72.0","lowerLimit":"64.9","upperLimit":"78.4"},{"groupId":"OG001","value":"75.0","lowerLimit":"60.4","upperLimit":"86.4"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"76.4","lowerLimit":"69.5","upperLimit":"82.3"},{"groupId":"OG001","value":"83.3","lowerLimit":"69.8","upperLimit":"92.5"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity Rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"94.2","lowerLimit":"89.5","upperLimit":"97.2"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"99.4","lowerLimit":"96.8","upperLimit":"100"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"81.9","lowerLimit":"75.3","upperLimit":"87.3"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"76.0","lowerLimit":"68.9","upperLimit":"82.2"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"96.3","lowerLimit":"89.4","upperLimit":"99.2"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"98.8","lowerLimit":"93.2","upperLimit":"100"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"71.3","lowerLimit":"60.0","upperLimit":"80.8"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"55.0","lowerLimit":"43.5","upperLimit":"66.2"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 1 [Month 0 (Day 1])","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 0 (Day 1)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"119"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus:Positive; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","lowerLimit":"64.5","upperLimit":"93.0"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","lowerLimit":"84.2","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","lowerLimit":"57.7","upperLimit":"88.9"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","lowerLimit":"71.8","upperLimit":"96.6"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","lowerLimit":"81.0","upperLimit":"90.8"},{"groupId":"OG001","value":"91.9","lowerLimit":"85.2","upperLimit":"96.2"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","lowerLimit":"96.5","upperLimit":"99.9"},{"groupId":"OG001","value":"99.1","lowerLimit":"95.1","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","lowerLimit":"65.2","upperLimit":"77.9"},{"groupId":"OG001","value":"78.4","lowerLimit":"69.6","upperLimit":"85.6"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","lowerLimit":"73.5","upperLimit":"84.9"},{"groupId":"OG001","value":"74.8","lowerLimit":"65.6","upperLimit":"82.5"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 2 (Month 12)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 12","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus:Positive; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","lowerLimit":"59.3","upperLimit":"93.2"},{"groupId":"OG001","value":"100","lowerLimit":"15.8","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"86.3","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"15.8","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","lowerLimit":"54.9","upperLimit":"90.6"},{"groupId":"OG001","value":"100","lowerLimit":"15.8","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","lowerLimit":"59.3","upperLimit":"93.2"},{"groupId":"OG001","value":"100","lowerLimit":"15.8","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","lowerLimit":"71.1","upperLimit":"84.5"},{"groupId":"OG001","value":"97.8","lowerLimit":"88.5","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"97.7","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"92.3","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","lowerLimit":"63.6","upperLimit":"78.3"},{"groupId":"OG001","value":"73.9","lowerLimit":"58.9","upperLimit":"85.7"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","lowerLimit":"68.3","upperLimit":"82.3"},{"groupId":"OG001","value":"82.6","lowerLimit":"68.6","upperLimit":"92.2"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus:Positive; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"67.6","upperLimit":"97.3"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"85.8","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","lowerLimit":"62.6","upperLimit":"95.3"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","lowerLimit":"57.8","upperLimit":"92.9"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","lowerLimit":"90.4","upperLimit":"98.1"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","lowerLimit":"96.3","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","lowerLimit":"74.4","upperLimit":"87.5"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","lowerLimit":"67.7","upperLimit":"82.2"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) ((DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus:Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"59.0","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"59.0","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"59.0","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus:Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","lowerLimit":"18.4","upperLimit":"90.1"}]}]},{"title":"Parent Trial Baseline Serostatus:Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","lowerLimit":"88.5","upperLimit":"99.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","lowerLimit":"92.6","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus; Negative:DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","lowerLimit":"56.6","upperLimit":"78.9"}]}]},{"title":"Parent Trial Baseline Serostatus; Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","lowerLimit":"42.7","upperLimit":"66.5"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 0 (Day 1)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"119"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"7.2","upperLimit":"15.5"},{"groupId":"OG001","value":"9.2","lowerLimit":"4.7","upperLimit":"15.9"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"20.5","lowerLimit":"15.6","upperLimit":"26.2"},{"groupId":"OG001","value":"18.5","lowerLimit":"12.0","upperLimit":"26.6"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"61.9","lowerLimit":"55.4","upperLimit":"68.1"},{"groupId":"OG001","value":"67.2","lowerLimit":"58.0","upperLimit":"75.6"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 12","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"12.6","lowerLimit":"8.2","upperLimit":"18.4"},{"groupId":"OG001","value":"10.4","lowerLimit":"3.5","upperLimit":"22.7"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"21.4","lowerLimit":"15.7","upperLimit":"28.1"},{"groupId":"OG001","value":"22.9","lowerLimit":"12.0","upperLimit":"37.3"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"57.1","lowerLimit":"49.6","upperLimit":"64.4"},{"groupId":"OG001","value":"66.7","lowerLimit":"51.6","upperLimit":"79.6"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for parent trial DEN-304.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"6.4","upperLimit":"16.1"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"17.0","lowerLimit":"11.7","upperLimit":"23.4"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"69.0","lowerLimit":"61.5","upperLimit":"75.8"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"11.9","upperLimit":"30.4"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"27.5","lowerLimit":"18.1","upperLimit":"38.6"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"48.8","lowerLimit":"37.4","upperLimit":"60.2"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 1 (Month 0 [Day 1])","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 0 (Day 1)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"119"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"1.9","upperLimit":"24.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"36.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"3.4","upperLimit":"28.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"36.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"51.3","upperLimit":"84.4"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"7.2","upperLimit":"16.3"},{"groupId":"OG001","value":"9.9","lowerLimit":"5.1","upperLimit":"17.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","lowerLimit":"16.4","upperLimit":"28.1"},{"groupId":"OG001","value":"19.8","lowerLimit":"12.9","upperLimit":"28.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"111"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","lowerLimit":"53.7","upperLimit":"67.4"},{"groupId":"OG001","value":"64.9","lowerLimit":"55.2","upperLimit":"73.7"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 2 (Month 12)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for both parent trials (DEN-304 and DEN-315).","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 12","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive:Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"0.1","upperLimit":"20.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"84.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive:Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"6.8","upperLimit":"40.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"84.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive:Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","lowerLimit":"42.5","upperLimit":"82.0"},{"groupId":"OG001","value":"100","lowerLimit":"15.8","upperLimit":"100"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative:Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"9.0","upperLimit":"20.4"},{"groupId":"OG001","value":"10.9","lowerLimit":"3.6","upperLimit":"23.6"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","lowerLimit":"15.5","upperLimit":"28.9"},{"groupId":"OG001","value":"23.9","lowerLimit":"12.6","upperLimit":"38.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","lowerLimit":"47.9","upperLimit":"64.0"},{"groupId":"OG001","value":"65.2","lowerLimit":"49.8","upperLimit":"78.6"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. (DEN-304). All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for parent trial DEN-304.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus; Positive: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"1.0","upperLimit":"27.0"}]}]},{"title":"Parent Trial Baseline Serostatus; Positive: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"1.0","upperLimit":"27.0"}]}]},{"title":"Parent Trial Baseline Serostatus; Positive: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"53.3","upperLimit":"90.2"}]}]},{"title":"Parent Trial Baseline Serostatus; Negative: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"6.4","upperLimit":"17.1"}]}]},{"title":"Parent Trial Baseline Serostatus; Negative: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","lowerLimit":"12.5","upperLimit":"25.6"}]}]},{"title":"Parent Trial Baseline Serostatus; Negative: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.0","lowerLimit":"59.8","upperLimit":"75.5"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus; Positive: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"41.0"}]}]},{"title":"Parent Trial Baseline Serostatus; Positive: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","lowerLimit":"9.9","upperLimit":"81.6"}]}]},{"title":"Parent Trial Baseline Serostatus; Positive: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","lowerLimit":"18.4","upperLimit":"90.1"}]}]},{"title":"Parent Trial Baseline Serostatus; Negative: Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","lowerLimit":"13.1","upperLimit":"33.1"}]}]},{"title":"Parent Trial Baseline Serostatus; Negative: Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","lowerLimit":"16.5","upperLimit":"37.6"}]}]},{"title":"Parent Trial Baseline Serostatus; Negative: Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.9","lowerLimit":"36.1","upperLimit":"60.0"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"Per Protocol Set-Booster (PPS-B) included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"100"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"116.2","lowerLimit":"86.6","upperLimit":"156.0"},{"groupId":"OG001","value":"120.7","lowerLimit":"86.9","upperLimit":"167.8"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"404.0","lowerLimit":"327.2","upperLimit":"498.8"},{"groupId":"OG001","value":"361.7","lowerLimit":"279.7","upperLimit":"467.9"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"32.3","lowerLimit":"24.8","upperLimit":"41.9"},{"groupId":"OG001","value":"30.1","lowerLimit":"22.5","upperLimit":"40.3"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"19.0","upperLimit":"33.0"},{"groupId":"OG001","value":"26.9","lowerLimit":"19.9","upperLimit":"36.3"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"110.8","lowerLimit":"82.2","upperLimit":"149.5"},{"groupId":"OG001","value":"1438.3","lowerLimit":"1104.0","upperLimit":"1873.8"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"363.4","lowerLimit":"291.8","upperLimit":"452.7"},{"groupId":"OG001","value":"1038.8","lowerLimit":"833.7","upperLimit":"1294.4"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"27.7","lowerLimit":"21.0","upperLimit":"36.5"},{"groupId":"OG001","value":"446.5","lowerLimit":"356.8","upperLimit":"558.8"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"23.6","lowerLimit":"17.9","upperLimit":"31.1"},{"groupId":"OG001","value":"361.6","lowerLimit":"277.6","upperLimit":"470.9"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 5, 6 months post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"94.2","lowerLimit":"66.9","upperLimit":"132.7"},{"groupId":"OG001","value":"464.9","lowerLimit":"336.1","upperLimit":"642.9"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"305.2","lowerLimit":"244.7","upperLimit":"380.7"},{"groupId":"OG001","value":"552.5","lowerLimit":"442.1","upperLimit":"690.5"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"27.4","lowerLimit":"21.4","upperLimit":"35.3"},{"groupId":"OG001","value":"159.5","lowerLimit":"122.6","upperLimit":"207.4"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"20.5","lowerLimit":"15.8","upperLimit":"26.7"},{"groupId":"OG001","value":"115.4","lowerLimit":"85.7","upperLimit":"155.2"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Pre-booster dose at Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"126.4","lowerLimit":"82.2","upperLimit":"194.4"},{"groupId":"OG001","value":"130.6","lowerLimit":"81.9","upperLimit":"208.4"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"583.9","lowerLimit":"448.5","upperLimit":"760.2"},{"groupId":"OG001","value":"596.6","lowerLimit":"453.4","upperLimit":"785.1"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"36.9","lowerLimit":"26.6","upperLimit":"51.3"},{"groupId":"OG001","value":"39.5","lowerLimit":"26.3","upperLimit":"59.6"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"34.1","lowerLimit":"23.7","upperLimit":"49.1"},{"groupId":"OG001","value":"34.1","lowerLimit":"22.3","upperLimit":"52.1"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 16) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"120.1","lowerLimit":"78.5","upperLimit":"184.0"},{"groupId":"OG001","value":"1254.3","lowerLimit":"862.2","upperLimit":"1824.5"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"499.2","lowerLimit":"379.7","upperLimit":"656.4"},{"groupId":"OG001","value":"1121.4","lowerLimit":"867.5","upperLimit":"1449.5"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"30.6","lowerLimit":"21.4","upperLimit":"43.5"},{"groupId":"OG001","value":"389.7","lowerLimit":"280.8","upperLimit":"540.8"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"31.0","lowerLimit":"21.5","upperLimit":"44.8"},{"groupId":"OG001","value":"275.4","lowerLimit":"197.8","upperLimit":"383.6"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 21) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"107.8","lowerLimit":"65.0","upperLimit":"179.0"},{"groupId":"OG001","value":"410.9","lowerLimit":"259.7","upperLimit":"650.1"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"433.0","lowerLimit":"321.4","upperLimit":"583.5"},{"groupId":"OG001","value":"689.4","lowerLimit":"530.6","upperLimit":"895.8"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"30.7","lowerLimit":"21.9","upperLimit":"42.9"},{"groupId":"OG001","value":"133.5","lowerLimit":"90.5","upperLimit":"197.0"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"27.3","lowerLimit":"18.7","upperLimit":"39.8"},{"groupId":"OG001","value":"93.7","lowerLimit":"63.7","upperLimit":"137.8"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Pre-booster dose at Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"102.6","lowerLimit":"70.6","upperLimit":"149.0"},{"groupId":"OG001","value":"106.7","lowerLimit":"68.3","upperLimit":"166.7"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"233.5","lowerLimit":"176.1","upperLimit":"309.8"},{"groupId":"OG001","value":"165.4","lowerLimit":"110.7","upperLimit":"247.1"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"26.4","lowerLimit":"17.0","upperLimit":"41.1"},{"groupId":"OG001","value":"19.6","lowerLimit":"13.6","upperLimit":"28.2"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"10.6","upperLimit":"23.5"},{"groupId":"OG001","value":"18.5","lowerLimit":"12.5","upperLimit":"27.4"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 43) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"37"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"98.4","lowerLimit":"65.1","upperLimit":"148.7"},{"groupId":"OG001","value":"1795.8","lowerLimit":"1273.5","upperLimit":"2532.5"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"227.5","lowerLimit":"164.5","upperLimit":"314.6"},{"groupId":"OG001","value":"917.6","lowerLimit":"607.2","upperLimit":"1386.7"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"24.0","lowerLimit":"15.2","upperLimit":"37.8"},{"groupId":"OG001","value":"556.8","lowerLimit":"431.6","upperLimit":"718.3"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"10.6","upperLimit":"23.5"},{"groupId":"OG001","value":"562.2","lowerLimit":"370.4","upperLimit":"853.1"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 48) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"6 months post-booster dose at Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"38"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"78.0","lowerLimit":"50.6","upperLimit":"120.2"},{"groupId":"OG001","value":"553.9","lowerLimit":"350.8","upperLimit":"874.6"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"187.0","lowerLimit":"142.3","upperLimit":"245.6"},{"groupId":"OG001","value":"403.4","lowerLimit":"275.1","upperLimit":"591.6"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"23.5","lowerLimit":"15.9","upperLimit":"34.6"},{"groupId":"OG001","value":"205.2","lowerLimit":"149.1","upperLimit":"282.5"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"13.8","lowerLimit":"9.9","upperLimit":"19.2"},{"groupId":"OG001","value":"155.1","lowerLimit":"97.0","upperLimit":"247.9"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"100"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"165.0","lowerLimit":"62.2","upperLimit":"437.8"},{"groupId":"OG001","value":"310.4","lowerLimit":"67.2","upperLimit":"1434.4"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"353.6","lowerLimit":"192.1","upperLimit":"650.8"},{"groupId":"OG001","value":"771.3","lowerLimit":"334.8","upperLimit":"1776.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","lowerLimit":"23.4","upperLimit":"123.6"},{"groupId":"OG001","value":"88.8","lowerLimit":"25.1","upperLimit":"313.4"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","lowerLimit":"17.4","upperLimit":"83.3"},{"groupId":"OG001","value":"57.0","lowerLimit":"12.9","upperLimit":"252.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110.4","lowerLimit":"80.8","upperLimit":"150.9"},{"groupId":"OG001","value":"106.1","lowerLimit":"77.2","upperLimit":"145.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"411.9","lowerLimit":"327.7","upperLimit":"517.8"},{"groupId":"OG001","value":"326.2","lowerLimit":"249.4","upperLimit":"426.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","lowerLimit":"22.7","upperLimit":"39.6"},{"groupId":"OG001","value":"26.0","lowerLimit":"19.6","upperLimit":"34.4"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","lowerLimit":"17.5","upperLimit":"31.7"},{"groupId":"OG001","value":"24.2","lowerLimit":"18.2","upperLimit":"32.3"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"170.5","lowerLimit":"59.7","upperLimit":"487.0"},{"groupId":"OG001","value":"1192.5","lowerLimit":"343.2","upperLimit":"4143.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"264.2","lowerLimit":"124.8","upperLimit":"559.2"},{"groupId":"OG001","value":"1533.3","lowerLimit":"720.1","upperLimit":"3264.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","lowerLimit":"16.9","upperLimit":"126.4"},{"groupId":"OG001","value":"286.5","lowerLimit":"124.6","upperLimit":"658.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","lowerLimit":"22.7","upperLimit":"78.4"},{"groupId":"OG001","value":"243.9","lowerLimit":"97.2","upperLimit":"612.3"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"104.4","lowerLimit":"76.2","upperLimit":"143.2"},{"groupId":"OG001","value":"1473.2","lowerLimit":"1129.4","upperLimit":"1921.6"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"379.8","lowerLimit":"301.1","upperLimit":"479.0"},{"groupId":"OG001","value":"988.3","lowerLimit":"783.4","upperLimit":"1246.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","lowerLimit":"19.4","upperLimit":"34.4"},{"groupId":"OG001","value":"472.6","lowerLimit":"374.1","upperLimit":"597.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","lowerLimit":"16.1","upperLimit":"29.5"},{"groupId":"OG001","value":"380.3","lowerLimit":"287.6","upperLimit":"502.8"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"166.2","lowerLimit":"48.3","upperLimit":"571.7"},{"groupId":"OG001","value":"435.8","lowerLimit":"106.8","upperLimit":"1777.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"278.9","lowerLimit":"108.9","upperLimit":"714.1"},{"groupId":"OG001","value":"699.2","lowerLimit":"305.0","upperLimit":"1603.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","lowerLimit":"18.8","upperLimit":"80.8"},{"groupId":"OG001","value":"137.1","lowerLimit":"44.9","upperLimit":"418.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","lowerLimit":"15.8","upperLimit":"57.6"},{"groupId":"OG001","value":"93.2","lowerLimit":"26.8","upperLimit":"324.4"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","lowerLimit":"61.5","upperLimit":"126.5"},{"groupId":"OG001","value":"469.4","lowerLimit":"338.9","upperLimit":"650.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"308.4","lowerLimit":"245.1","upperLimit":"387.9"},{"groupId":"OG001","value":"533.4","lowerLimit":"422.9","upperLimit":"672.6"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","lowerLimit":"20.1","upperLimit":"34.5"},{"groupId":"OG001","value":"163.1","lowerLimit":"125.1","upperLimit":"212.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","lowerLimit":"14.7","upperLimit":"26.2"},{"groupId":"OG001","value":"119.1","lowerLimit":"88.2","upperLimit":"160.8"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Pre-booster dose at Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"120.5","lowerLimit":"37.2","upperLimit":"390.0"},{"groupId":"OG001","value":"368.4","lowerLimit":"44.6","upperLimit":"3040.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"368.8","lowerLimit":"175.4","upperLimit":"775.7"},{"groupId":"OG001","value":"839.4","lowerLimit":"298.9","upperLimit":"2357.3"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","lowerLimit":"19.3","upperLimit":"80.6"},{"groupId":"OG001","value":"102.1","lowerLimit":"19.0","upperLimit":"549.3"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","lowerLimit":"12.9","upperLimit":"60.2"},{"groupId":"OG001","value":"79.0","lowerLimit":"13.1","upperLimit":"475.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"127.6","lowerLimit":"79.0","upperLimit":"206.0"},{"groupId":"OG001","value":"109.2","lowerLimit":"70.2","upperLimit":"169.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"639.0","lowerLimit":"480.4","upperLimit":"849.9"},{"groupId":"OG001","value":"562.4","lowerLimit":"423.1","upperLimit":"747.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","lowerLimit":"25.0","upperLimit":"53.2"},{"groupId":"OG001","value":"33.6","lowerLimit":"22.5","upperLimit":"50.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","lowerLimit":"23.4","upperLimit":"53.9"},{"groupId":"OG001","value":"29.5","lowerLimit":"19.5","upperLimit":"44.6"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 16) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"125.6","lowerLimit":"32.3","upperLimit":"488.7"},{"groupId":"OG001","value":"1124.7","lowerLimit":"182.3","upperLimit":"6939.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"264.3","lowerLimit":"105.0","upperLimit":"665.2"},{"groupId":"OG001","value":"1545.0","lowerLimit":"528.1","upperLimit":"4519.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","lowerLimit":"11.6","upperLimit":"74.3"},{"groupId":"OG001","value":"239.1","lowerLimit":"72.7","upperLimit":"786.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.2","lowerLimit":"22.4","upperLimit":"46.2"},{"groupId":"OG001","value":"202.8","lowerLimit":"57.6","upperLimit":"714.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"119.2","lowerLimit":"75.0","upperLimit":"189.3"},{"groupId":"OG001","value":"1275.5","lowerLimit":"879.5","upperLimit":"1849.6"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"559.8","lowerLimit":"422.3","upperLimit":"742.0"},{"groupId":"OG001","value":"1067.4","lowerLimit":"820.0","upperLimit":"1389.6"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"20.7","upperLimit":"45.8"},{"groupId":"OG001","value":"420.1","lowerLimit":"297.4","upperLimit":"593.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"20.0","upperLimit":"47.5"},{"groupId":"OG001","value":"288.7","lowerLimit":"203.6","upperLimit":"409.4"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 21) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"154.2","lowerLimit":"30.2","upperLimit":"786.6"},{"groupId":"OG001","value":"461.7","lowerLimit":"68.8","upperLimit":"3098.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"337.6","lowerLimit":"104.5","upperLimit":"1090.2"},{"groupId":"OG001","value":"825.4","lowerLimit":"309.0","upperLimit":"2205.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","lowerLimit":"14.4","upperLimit":"98.0"},{"groupId":"OG001","value":"145.5","lowerLimit":"32.0","upperLimit":"661.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","lowerLimit":"12.4","upperLimit":"61.0"},{"groupId":"OG001","value":"95.7","lowerLimit":"21.6","upperLimit":"423.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"101.6","lowerLimit":"58.6","upperLimit":"176.2"},{"groupId":"OG001","value":"401.4","lowerLimit":"254.9","upperLimit":"632.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"451.4","lowerLimit":"330.8","upperLimit":"615.9"},{"groupId":"OG001","value":"665.0","lowerLimit":"508.0","upperLimit":"870.6"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","lowerLimit":"20.5","upperLimit":"43.0"},{"groupId":"OG001","value":"131.3","lowerLimit":"88.3","upperLimit":"195.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","lowerLimit":"17.7","upperLimit":"41.8"},{"groupId":"OG001","value":"93.3","lowerLimit":"62.9","upperLimit":"138.4"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Pre-booster dose at Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"470.4","lowerLimit":"25.4","upperLimit":"8709.7"},{"groupId":"OG001","value":"185.7","lowerLimit":"11.7","upperLimit":"2940.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"307.1","lowerLimit":"19.8","upperLimit":"4754.2"},{"groupId":"OG001","value":"598.4","lowerLimit":"15.8","upperLimit":"22694.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"151.1","lowerLimit":"0.7","upperLimit":"34960.6"},{"groupId":"OG001","value":"58.2","lowerLimit":"1.5","upperLimit":"2257.4"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"107.2","lowerLimit":"1.7","upperLimit":"6684.4"},{"groupId":"OG001","value":"21.4","lowerLimit":"0.0","upperLimit":"11250.6"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","lowerLimit":"63.1","upperLimit":"131.1"},{"groupId":"OG001","value":"101.9","lowerLimit":"63.5","upperLimit":"163.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"228.5","lowerLimit":"170.5","upperLimit":"306.3"},{"groupId":"OG001","value":"148.6","lowerLimit":"99.7","upperLimit":"221.4"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","lowerLimit":"15.2","upperLimit":"34.8"},{"groupId":"OG001","value":"17.9","lowerLimit":"12.5","upperLimit":"25.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"9.4","upperLimit":"19.5"},{"groupId":"OG001","value":"18.3","lowerLimit":"12.6","upperLimit":"26.6"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 43) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"37"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"427.0","lowerLimit":"45.4","upperLimit":"4020.4"},{"groupId":"OG001","value":"1393.8","lowerLimit":"219.3","upperLimit":"8859.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"264.1","lowerLimit":"8.7","upperLimit":"8032.8"},{"groupId":"OG001","value":"1502.5","lowerLimit":"236.0","upperLimit":"9565.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"180.8","lowerLimit":"1.1","upperLimit":"29718.0"},{"groupId":"OG001","value":"464.2","lowerLimit":"204.7","upperLimit":"1052.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","lowerLimit":"1.2","upperLimit":"7265.6"},{"groupId":"OG001","value":"398.9","lowerLimit":"35.2","upperLimit":"4522.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","lowerLimit":"57.6","upperLimit":"132.5"},{"groupId":"OG001","value":"1836.5","lowerLimit":"1269.6","upperLimit":"2656.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"224.8","lowerLimit":"160.9","upperLimit":"314.1"},{"groupId":"OG001","value":"878.5","lowerLimit":"563.9","upperLimit":"1368.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","lowerLimit":"13.4","upperLimit":"31.0"},{"groupId":"OG001","value":"565.8","lowerLimit":"429.2","upperLimit":"745.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","lowerLimit":"9.4","upperLimit":"19.7"},{"groupId":"OG001","value":"579.4","lowerLimit":"370.7","upperLimit":"905.6"}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 48) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"6 months post-booster dose at Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"38"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"223.9","lowerLimit":"31.8","upperLimit":"1574.3"},{"groupId":"OG001","value":"366.4","lowerLimit":"8.2","upperLimit":"16297.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"129.9","lowerLimit":"0.8","upperLimit":"21199.9"},{"groupId":"OG001","value":"425.0","lowerLimit":"9.5","upperLimit":"19098.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","lowerLimit":"6.5","upperLimit":"319.1"},{"groupId":"OG001","value":"114.5","lowerLimit":"6.0","upperLimit":"2196.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","lowerLimit":"0.0","upperLimit":"55722.2"},{"groupId":"OG001","value":"86.2","lowerLimit":"0.2","upperLimit":"42114.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","lowerLimit":"47.1","upperLimit":"115.6"},{"groupId":"OG001","value":"573.9","lowerLimit":"355.3","upperLimit":"927.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"190.6","lowerLimit":"143.4","upperLimit":"253.4"},{"groupId":"OG001","value":"401.6","lowerLimit":"269.9","upperLimit":"597.6"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","lowerLimit":"15.1","upperLimit":"34.0"},{"groupId":"OG001","value":"215.7","lowerLimit":"155.4","upperLimit":"299.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","lowerLimit":"9.3","upperLimit":"18.1"},{"groupId":"OG001","value":"163.1","lowerLimit":"102.6","upperLimit":"259.1"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"100"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"98.0","lowerLimit":"93.1","upperLimit":"99.8"},{"groupId":"OG001","value":"94.0","lowerLimit":"87.4","upperLimit":"97.8"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.4","upperLimit":"100.0"},{"groupId":"OG001","value":"99.0","lowerLimit":"94.6","upperLimit":"100.0"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"80.4","lowerLimit":"71.4","upperLimit":"87.6"},{"groupId":"OG001","value":"73.0","lowerLimit":"63.2","upperLimit":"81.4"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"66.7","lowerLimit":"56.6","upperLimit":"75.7"},{"groupId":"OG001","value":"67.0","lowerLimit":"56.9","upperLimit":"76.1"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"98.0","lowerLimit":"92.9","upperLimit":"99.8"},{"groupId":"OG001","value":"100","lowerLimit":"96.3","upperLimit":"100.0"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.3","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"96.3","upperLimit":"100.0"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"71.7","lowerLimit":"61.8","upperLimit":"80.3"},{"groupId":"OG001","value":"100","lowerLimit":"96.3","upperLimit":"100.0"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"66.7","lowerLimit":"56.5","upperLimit":"75.8"},{"groupId":"OG001","value":"100","lowerLimit":"96.3","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"90.6","lowerLimit":"82.9","upperLimit":"95.6"},{"groupId":"OG001","value":"96.7","lowerLimit":"90.8","upperLimit":"99.3"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"96.1","upperLimit":"100.0"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"76.0","lowerLimit":"66.3","upperLimit":"84.2"},{"groupId":"OG001","value":"98.9","lowerLimit":"94.1","upperLimit":"100.0"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"63.5","lowerLimit":"53.1","upperLimit":"73.1"},{"groupId":"OG001","value":"94.6","lowerLimit":"87.8","upperLimit":"98.2"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"96.7","lowerLimit":"88.7","upperLimit":"99.6"},{"groupId":"OG001","value":"95.1","lowerLimit":"86.3","upperLimit":"99.0"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"94.1","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"94.1","upperLimit":"100.0"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"83.6","lowerLimit":"71.9","upperLimit":"91.8"},{"groupId":"OG001","value":"77.0","lowerLimit":"64.5","upperLimit":"86.8"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"75.4","lowerLimit":"62.7","upperLimit":"85.5"},{"groupId":"OG001","value":"72.1","lowerLimit":"59.2","upperLimit":"82.9"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"98.3","lowerLimit":"90.9","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"94.0","upperLimit":"100.0"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"93.9","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"94.0","upperLimit":"100.0"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"74.6","lowerLimit":"61.6","upperLimit":"85.0"},{"groupId":"OG001","value":"100","lowerLimit":"94.0","upperLimit":"100.0"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"76.3","lowerLimit":"63.4","upperLimit":"86.4"},{"groupId":"OG001","value":"100","lowerLimit":"94.0","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"89.3","lowerLimit":"78.1","upperLimit":"96.0"},{"groupId":"OG001","value":"96.3","lowerLimit":"87.3","upperLimit":"99.5"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"93.6","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"93.4","upperLimit":"100.0"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"78.6","lowerLimit":"65.6","upperLimit":"88.4"},{"groupId":"OG001","value":"98.1","lowerLimit":"90.1","upperLimit":"100.0"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"71.4","lowerLimit":"57.8","upperLimit":"82.7"},{"groupId":"OG001","value":"96.3","lowerLimit":"87.3","upperLimit":"99.5"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"91.4","upperLimit":"100.0"},{"groupId":"OG001","value":"92.3","lowerLimit":"79.1","upperLimit":"98.4"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"91.4","upperLimit":"100.0"},{"groupId":"OG001","value":"97.4","lowerLimit":"86.5","upperLimit":"99.9"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"75.6","lowerLimit":"59.7","upperLimit":"87.6"},{"groupId":"OG001","value":"66.7","lowerLimit":"49.8","upperLimit":"80.9"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"53.7","lowerLimit":"37.4","upperLimit":"69.3"},{"groupId":"OG001","value":"59.0","lowerLimit":"42.1","upperLimit":"74.4"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"37"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"97.5","lowerLimit":"86.8","upperLimit":"99.9"},{"groupId":"OG001","value":"100","lowerLimit":"90.5","upperLimit":"100.0"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"91.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"90.5","upperLimit":"100.0"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"67.5","lowerLimit":"50.9","upperLimit":"81.4"},{"groupId":"OG001","value":"100","lowerLimit":"90.5","upperLimit":"100.0"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"52.5","lowerLimit":"36.1","upperLimit":"68.5"},{"groupId":"OG001","value":"100","lowerLimit":"90.5","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"38"}]}],"classes":[{"title":"DENV-1","categories":[{"measurements":[{"groupId":"OG000","value":"92.5","lowerLimit":"79.6","upperLimit":"98.4"},{"groupId":"OG001","value":"97.4","lowerLimit":"86.2","upperLimit":"99.9"}]}]},{"title":"DENV-2","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"91.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"90.7","upperLimit":"100.0"}]}]},{"title":"DENV-3","categories":[{"measurements":[{"groupId":"OG000","value":"72.5","lowerLimit":"56.1","upperLimit":"85.4"},{"groupId":"OG001","value":"100","lowerLimit":"90.7","upperLimit":"100.0"}]}]},{"title":"DENV-4","categories":[{"measurements":[{"groupId":"OG000","value":"52.5","lowerLimit":"36.1","upperLimit":"68.5"},{"groupId":"OG001","value":"92.1","lowerLimit":"78.6","upperLimit":"98.3"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"100"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","lowerLimit":"64.0","upperLimit":"99.8"},{"groupId":"OG001","value":"91.7","lowerLimit":"61.5","upperLimit":"99.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"75.3","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"73.5","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","lowerLimit":"64.0","upperLimit":"99.8"},{"groupId":"OG001","value":"83.3","lowerLimit":"51.6","upperLimit":"97.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","lowerLimit":"54.6","upperLimit":"98.1"},{"groupId":"OG001","value":"66.7","lowerLimit":"34.9","upperLimit":"90.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","lowerLimit":"93.9","upperLimit":"100.0"},{"groupId":"OG001","value":"94.3","lowerLimit":"87.2","upperLimit":"98.1"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"95.9","upperLimit":"100.0"},{"groupId":"OG001","value":"98.9","lowerLimit":"93.8","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","lowerLimit":"68.7","upperLimit":"86.6"},{"groupId":"OG001","value":"71.6","lowerLimit":"61.0","upperLimit":"80.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","lowerLimit":"53.2","upperLimit":"73.9"},{"groupId":"OG001","value":"67.0","lowerLimit":"56.2","upperLimit":"76.7"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","lowerLimit":"61.5","upperLimit":"99.8"},{"groupId":"OG001","value":"100","lowerLimit":"71.5","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"73.5","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"71.5","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","lowerLimit":"51.6","upperLimit":"97.9"},{"groupId":"OG001","value":"100","lowerLimit":"71.5","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"73.5","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"71.5","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","lowerLimit":"93.8","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"95.8","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"95.8","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"95.8","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","lowerLimit":"59.4","upperLimit":"79.5"},{"groupId":"OG001","value":"100","lowerLimit":"95.8","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.1","lowerLimit":"51.0","upperLimit":"72.3"},{"groupId":"OG001","value":"100","lowerLimit":"95.8","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"55.5","upperLimit":"99.7"},{"groupId":"OG001","value":"91.7","lowerLimit":"61.5","upperLimit":"99.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"69.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"73.5","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"55.5","upperLimit":"99.7"},{"groupId":"OG001","value":"91.7","lowerLimit":"61.5","upperLimit":"99.8"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"55.5","upperLimit":"99.7"},{"groupId":"OG001","value":"83.3","lowerLimit":"51.6","upperLimit":"97.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","lowerLimit":"82.5","upperLimit":"95.9"},{"groupId":"OG001","value":"97.5","lowerLimit":"91.3","upperLimit":"99.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"95.8","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"95.5","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","lowerLimit":"63.9","upperLimit":"83.2"},{"groupId":"OG001","value":"100","lowerLimit":"95.5","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","lowerLimit":"49.3","upperLimit":"70.8"},{"groupId":"OG001","value":"96.3","lowerLimit":"89.4","upperLimit":"99.2"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"55.5","upperLimit":"99.7"},{"groupId":"OG001","value":"88.9","lowerLimit":"51.8","upperLimit":"99.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"69.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"66.4","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"55.5","upperLimit":"99.7"},{"groupId":"OG001","value":"77.8","lowerLimit":"40.0","upperLimit":"97.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","lowerLimit":"44.4","upperLimit":"97.5"},{"groupId":"OG001","value":"77.8","lowerLimit":"40.0","upperLimit":"97.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","lowerLimit":"89.6","upperLimit":"100.0"},{"groupId":"OG001","value":"96.2","lowerLimit":"86.8","upperLimit":"99.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"93.0","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"93.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.4","lowerLimit":"69.1","upperLimit":"91.6"},{"groupId":"OG001","value":"76.9","lowerLimit":"63.2","upperLimit":"87.5"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","lowerLimit":"60.4","upperLimit":"85.7"},{"groupId":"OG001","value":"71.2","lowerLimit":"56.9","upperLimit":"82.9"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","lowerLimit":"51.8","upperLimit":"99.7"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"66.4","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","lowerLimit":"40.0","upperLimit":"97.2"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"66.4","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"92.9","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"93.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"92.9","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"93.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","lowerLimit":"59.7","upperLimit":"85.4"},{"groupId":"OG001","value":"100","lowerLimit":"93.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","lowerLimit":"57.5","upperLimit":"83.8"},{"groupId":"OG001","value":"100","lowerLimit":"93.2","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"47.3","upperLimit":"99.7"},{"groupId":"OG001","value":"88.9","lowerLimit":"51.8","upperLimit":"99.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"63.1","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"66.4","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"47.3","upperLimit":"99.7"},{"groupId":"OG001","value":"88.9","lowerLimit":"51.8","upperLimit":"99.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"47.3","upperLimit":"99.7"},{"groupId":"OG001","value":"88.9","lowerLimit":"51.8","upperLimit":"99.7"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","lowerLimit":"77.3","upperLimit":"96.5"},{"groupId":"OG001","value":"97.8","lowerLimit":"88.2","upperLimit":"99.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"92.6","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"92.1","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","lowerLimit":"62.7","upperLimit":"88.0"},{"groupId":"OG001","value":"100","lowerLimit":"92.1","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","lowerLimit":"53.7","upperLimit":"81.3"},{"groupId":"OG001","value":"97.8","lowerLimit":"88.2","upperLimit":"99.9"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"33.3","lowerLimit":"0.8","upperLimit":"90.6"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"90.7","upperLimit":"100.0"},{"groupId":"OG001","value":"91.7","lowerLimit":"77.5","upperLimit":"98.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"90.7","upperLimit":"100.0"},{"groupId":"OG001","value":"97.2","lowerLimit":"85.5","upperLimit":"99.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","lowerLimit":"56.9","upperLimit":"86.6"},{"groupId":"OG001","value":"63.9","lowerLimit":"46.2","upperLimit":"79.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"33.4","upperLimit":"66.6"},{"groupId":"OG001","value":"61.1","lowerLimit":"43.5","upperLimit":"76.9"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"37"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","lowerLimit":"85.8","upperLimit":"99.9"},{"groupId":"OG001","value":"100","lowerLimit":"89.7","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"90.5","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"89.7","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.9","lowerLimit":"47.5","upperLimit":"79.8"},{"groupId":"OG001","value":"100","lowerLimit":"89.7","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","lowerLimit":"31.9","upperLimit":"65.6"},{"groupId":"OG001","value":"100","lowerLimit":"89.7","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Visit 3 (Month 15) for participants from parent trials DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"38"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus;Positive: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"15.8","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"15.8","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"15.8","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Positive: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"15.8","upperLimit":"100.0"},{"groupId":"OG001","value":"66.7","lowerLimit":"9.4","upperLimit":"99.2"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","lowerLimit":"78.6","upperLimit":"98.3"},{"groupId":"OG001","value":"97.1","lowerLimit":"85.1","upperLimit":"99.9"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"90.7","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"90.0","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","lowerLimit":"54.1","upperLimit":"84.6"},{"groupId":"OG001","value":"100","lowerLimit":"90.0","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus;Negative: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"33.4","upperLimit":"66.6"},{"groupId":"OG001","value":"94.3","lowerLimit":"80.8","upperLimit":"99.3"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose at Visit 3 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"100"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"15.7","lowerLimit":"9.2","upperLimit":"24.2"},{"groupId":"OG001","value":"16.0","lowerLimit":"9.4","upperLimit":"24.7"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"20.6","lowerLimit":"13.2","upperLimit":"29.7"},{"groupId":"OG001","value":"20.0","lowerLimit":"12.7","upperLimit":"29.2"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"62.7","lowerLimit":"52.6","upperLimit":"72.1"},{"groupId":"OG001","value":"59.0","lowerLimit":"48.7","upperLimit":"68.7"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"18.2","lowerLimit":"11.1","upperLimit":"27.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.7"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"24.2","lowerLimit":"16.2","upperLimit":"33.9"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.7"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"56.6","lowerLimit":"46.2","upperLimit":"66.5"},{"groupId":"OG001","value":"100","lowerLimit":"96.3","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose at Visit 5 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"14.6","lowerLimit":"8.2","upperLimit":"23.3"},{"groupId":"OG001","value":"2.2","lowerLimit":"0.3","upperLimit":"7.6"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"21.9","lowerLimit":"14.1","upperLimit":"31.5"},{"groupId":"OG001","value":"5.4","lowerLimit":"1.8","upperLimit":"12.2"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"57.3","lowerLimit":"46.8","upperLimit":"67.3"},{"groupId":"OG001","value":"92.4","lowerLimit":"84.9","upperLimit":"96.9"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"4.7","upperLimit":"22.2"},{"groupId":"OG001","value":"14.8","lowerLimit":"7.0","upperLimit":"26.2"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"16.4","lowerLimit":"8.2","upperLimit":"28.1"},{"groupId":"OG001","value":"16.4","lowerLimit":"8.2","upperLimit":"28.1"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"70.5","lowerLimit":"57.4","upperLimit":"81.5"},{"groupId":"OG001","value":"65.6","lowerLimit":"52.3","upperLimit":"77.3"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 16 (DEN-304.)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"15.3","lowerLimit":"7.2","upperLimit":"27.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.0"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"20.3","lowerLimit":"11.0","upperLimit":"32.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.0"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"64.4","lowerLimit":"50.9","upperLimit":"76.4"},{"groupId":"OG001","value":"100","lowerLimit":"94.0","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"6.4","upperLimit":"26.2"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.0","upperLimit":"9.9"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"7.6","upperLimit":"28.3"},{"groupId":"OG001","value":"5.6","lowerLimit":"1.2","upperLimit":"15.4"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"64.3","lowerLimit":"50.4","upperLimit":"76.6"},{"groupId":"OG001","value":"92.6","lowerLimit":"82.1","upperLimit":"97.9"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"22.0","lowerLimit":"10.6","upperLimit":"37.6"},{"groupId":"OG001","value":"17.9","lowerLimit":"7.5","upperLimit":"33.5"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"26.8","lowerLimit":"14.2","upperLimit":"42.9"},{"groupId":"OG001","value":"25.6","lowerLimit":"13.0","upperLimit":"42.1"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"51.2","lowerLimit":"35.1","upperLimit":"67.1"},{"groupId":"OG001","value":"48.7","lowerLimit":"32.4","upperLimit":"65.2"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 1 Month Post-Booster Dose at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"37"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"22.5","lowerLimit":"10.8","upperLimit":"38.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"9.5"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"30.0","lowerLimit":"16.6","upperLimit":"46.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"9.5"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"45.0","lowerLimit":"29.3","upperLimit":"61.5"},{"groupId":"OG001","value":"100","lowerLimit":"90.5","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-booster Dose at 6 Months Post-Booster Dose at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-Booster dose at Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"38"}]}],"classes":[{"title":"Bivalent","categories":[{"measurements":[{"groupId":"OG000","value":"15.0","lowerLimit":"5.7","upperLimit":"29.8"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"Trivalent","categories":[{"measurements":[{"groupId":"OG000","value":"30.0","lowerLimit":"16.6","upperLimit":"46.5"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.6","upperLimit":"17.7"}]}]},{"title":"Tetravalent","categories":[{"measurements":[{"groupId":"OG000","value":"47.5","lowerLimit":"31.5","upperLimit":"63.9"},{"groupId":"OG001","value":"92.1","lowerLimit":"78.6","upperLimit":"98.3"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\ any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"100"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"},{"groupId":"OG001","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"},{"groupId":"OG001","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","lowerLimit":"46.2","upperLimit":"95.0"},{"groupId":"OG001","value":"66.7","lowerLimit":"34.9","upperLimit":"90.1"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","lowerLimit":"9.8","upperLimit":"26.3"},{"groupId":"OG001","value":"17.0","lowerLimit":"9.9","upperLimit":"26.6"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","lowerLimit":"13.4","upperLimit":"31.3"},{"groupId":"OG001","value":"20.5","lowerLimit":"12.6","upperLimit":"30.4"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","lowerLimit":"49.7","upperLimit":"70.9"},{"groupId":"OG001","value":"58.0","lowerLimit":"47.0","upperLimit":"68.4"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\ any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 16 (DEN-304) and Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"28.5"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"28.5"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","lowerLimit":"51.6","upperLimit":"97.9"},{"groupId":"OG001","value":"100","lowerLimit":"71.5","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","lowerLimit":"11.8","upperLimit":"29.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"4.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","lowerLimit":"17.6","upperLimit":"37.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"4.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","lowerLimit":"41.9","upperLimit":"63.7"},{"groupId":"OG001","value":"100","lowerLimit":"95.8","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 21 (DEN-304) and Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"30.8"},{"groupId":"OG001","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"30.8"},{"groupId":"OG001","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"55.5","upperLimit":"99.7"},{"groupId":"OG001","value":"75.0","lowerLimit":"42.8","upperLimit":"94.5"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","lowerLimit":"9.2","upperLimit":"25.8"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","lowerLimit":"15.8","upperLimit":"34.9"},{"groupId":"OG001","value":"3.8","lowerLimit":"0.8","upperLimit":"10.6"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","lowerLimit":"42.4","upperLimit":"64.3"},{"groupId":"OG001","value":"95.0","lowerLimit":"87.7","upperLimit":"98.6"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\ any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 15 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","lowerLimit":"0.3","upperLimit":"44.5"},{"groupId":"OG001","value":"11.1","lowerLimit":"0.3","upperLimit":"48.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"2.5","upperLimit":"55.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"33.6"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","lowerLimit":"34.8","upperLimit":"93.3"},{"groupId":"OG001","value":"77.8","lowerLimit":"40.0","upperLimit":"97.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","lowerLimit":"4.4","upperLimit":"23.9"},{"groupId":"OG001","value":"15.4","lowerLimit":"6.9","upperLimit":"28.1"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","lowerLimit":"7.0","upperLimit":"28.6"},{"groupId":"OG001","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","lowerLimit":"56.2","upperLimit":"82.5"},{"groupId":"OG001","value":"63.5","lowerLimit":"49.0","upperLimit":"76.4"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 16 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"0.3","upperLimit":"48.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"36.9"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"0.3","upperLimit":"48.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"36.9"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","lowerLimit":"40.0","upperLimit":"97.2"},{"groupId":"OG001","value":"100","lowerLimit":"63.1","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"7.2","upperLimit":"29.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","lowerLimit":"11.5","upperLimit":"36.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","lowerLimit":"47.2","upperLimit":"75.3"},{"groupId":"OG001","value":"100","lowerLimit":"93.2","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-booster dose at Month 21 (DEN-304)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"36.9"},{"groupId":"OG001","value":"11.1","lowerLimit":"0.3","upperLimit":"48.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"36.9"},{"groupId":"OG001","value":"11.1","lowerLimit":"0.3","upperLimit":"48.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"47.3","upperLimit":"99.7"},{"groupId":"OG001","value":"77.8","lowerLimit":"40.0","upperLimit":"97.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","lowerLimit":"7.5","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"7.9"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"8.9","upperLimit":"32.6"},{"groupId":"OG001","value":"4.4","lowerLimit":"0.5","upperLimit":"15.1"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","lowerLimit":"45.3","upperLimit":"74.2"},{"groupId":"OG001","value":"95.6","lowerLimit":"84.9","upperLimit":"99.5"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Pre-booster dose at Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"70.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"70.8"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"70.8"},{"groupId":"OG001","value":"66.7","lowerLimit":"9.4","upperLimit":"99.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"33.3","lowerLimit":"0.8","upperLimit":"90.6"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","lowerLimit":"11.4","upperLimit":"40.2"},{"groupId":"OG001","value":"19.4","lowerLimit":"8.2","upperLimit":"36.0"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","lowerLimit":"15.4","upperLimit":"45.9"},{"groupId":"OG001","value":"22.2","lowerLimit":"10.1","upperLimit":"39.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","lowerLimit":"31.0","upperLimit":"64.2"},{"groupId":"OG001","value":"50.0","lowerLimit":"32.9","upperLimit":"67.1"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"1 month post-booster dose at Month 43 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"37"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"70.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"70.8"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"70.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"70.8"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"29.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"29.2","upperLimit":"100.0"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","lowerLimit":"11.8","upperLimit":"41.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","lowerLimit":"18.0","upperLimit":"49.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.5","lowerLimit":"24.8","upperLimit":"57.9"},{"groupId":"OG001","value":"100","lowerLimit":"89.7","upperLimit":"100.0"}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-booster Dose at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Overall number of participants analyzed: number of participants with data available for analyses. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"6 months post-Booster dose at Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"38"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"84.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"70.8"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"84.2"},{"groupId":"OG001","value":"33.3","lowerLimit":"0.8","upperLimit":"90.6"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"15.8","upperLimit":"100.0"},{"groupId":"OG001","value":"66.7","lowerLimit":"9.4","upperLimit":"99.2"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Bivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"6.0","upperLimit":"31.3"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.1","upperLimit":"14.9"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Trivalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","lowerLimit":"17.5","upperLimit":"48.7"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.1","upperLimit":"14.9"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Tetravalent","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","lowerLimit":"28.6","upperLimit":"61.7"},{"groupId":"OG001","value":"94.3","lowerLimit":"80.8","upperLimit":"99.3"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio (GMR) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes for All Participants Prior to the Booster Dose","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"unitless ratio","timeFrame":"Month 12 vs Month 0, Month 15 (DEN-304) vs parent trial Month 4, Mont 42 (DEN315) vs parent trial Month 4, Month 0 vs parent trial Month 9, Month 12 vs parent trial Month 9","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"119"}]}],"classes":[{"title":"Month 12 vs Month 0: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.753","lowerLimit":"0.675","upperLimit":"0.840"},{"groupId":"OG001","value":"0.891","lowerLimit":"0.741","upperLimit":"1.071"}]}]},{"title":"Month 12 vs Month 0: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.698","lowerLimit":"0.650","upperLimit":"0.749"},{"groupId":"OG001","value":"0.622","lowerLimit":"0.548","upperLimit":"0.705"}]}]},{"title":"Month 12 vs Month 0: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.864","lowerLimit":"0.791","upperLimit":"0.945"},{"groupId":"OG001","value":"0.852","lowerLimit":"0.668","upperLimit":"1.088"}]}]},{"title":"Month 12 vs Month 0: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.691","lowerLimit":"0.634","upperLimit":"0.754"},{"groupId":"OG001","value":"0.861","lowerLimit":"0.708","upperLimit":"1.046"}]}]},{"title":"Month 15 (DEN-304) vs Parent Trial Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.438","lowerLimit":"0.382","upperLimit":"0.502"}]}]},{"title":"Month 15 (DEN-304) vs Parent Trial Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.159","lowerLimit":"0.137","upperLimit":"0.185"}]}]},{"title":"Month 15 (DEN-304) vs Parent Trial Month 4: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.275","lowerLimit":"0.241","upperLimit":"0.315"}]}]},{"title":"Month 15 (DEN-304) vs Parent Trial Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.238","lowerLimit":"0.201","upperLimit":"0.281"}]}]},{"title":"Month 42 (DEN-315) vs Parent Trial Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.296","lowerLimit":"0.240","upperLimit":"0.366"}]}]},{"title":"Month 42 (DEN-315) vs Parent Trial Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.108","lowerLimit":"0.089","upperLimit":"0.130"}]}]},{"title":"Month 42 (DEN-315) vs Parent Trial Month 4: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.202","lowerLimit":"0.162","upperLimit":"0.252"}]}]},{"title":"Month 42 (DEN-315) vs Parent Trial Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.095","lowerLimit":"0.076","upperLimit":"0.118"}]}]},{"title":"Month 0 vs Parent Trial Month 9: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"110"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.529","lowerLimit":"0.482","upperLimit":"0.582"},{"groupId":"OG001","value":"0.517","lowerLimit":"0.455","upperLimit":"0.587"}]}]},{"title":"Month 0 vs Parent Trial Month 9: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"110"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.396","lowerLimit":"0.369","upperLimit":"0.426"},{"groupId":"OG001","value":"0.466","lowerLimit":"0.415","upperLimit":"0.522"}]}]},{"title":"Month 0 vs Parent Trial Month 9: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"110"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.440","lowerLimit":"0.394","upperLimit":"0.492"},{"groupId":"OG001","value":"0.547","lowerLimit":"0.477","upperLimit":"0.629"}]}]},{"title":"Month 0 vs Parent Trial Month 9: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"110"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.577","lowerLimit":"0.518","upperLimit":"0.641"},{"groupId":"OG001","value":"0.568","lowerLimit":"0.504","upperLimit":"0.641"}]}]},{"title":"Month 12 vs Parent Trial Month 9: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.415","lowerLimit":"0.367","upperLimit":"0.470"},{"groupId":"OG001","value":"0.486","lowerLimit":"0.377","upperLimit":"0.627"}]}]},{"title":"Month 12 vs Parent Trial Month 9: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.265","lowerLimit":"0.239","upperLimit":"0.295"},{"groupId":"OG001","value":"0.289","lowerLimit":"0.238","upperLimit":"0.351"}]}]},{"title":"Month 12 vs Parent Trial Month 9: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.407","lowerLimit":"0.353","upperLimit":"0.470"},{"groupId":"OG001","value":"0.435","lowerLimit":"0.336","upperLimit":"0.562"}]}]},{"title":"Month 12 vs Parent Trial Month 9: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.385","lowerLimit":"0.336","upperLimit":"0.442"},{"groupId":"OG001","value":"0.567","lowerLimit":"0.431","upperLimit":"0.745"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio (GMR) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes by Serostatus at Baseline in the Parent Trials Prior to the Booster Dose","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial.","populationDescription":"PPS included all participants from the FAS who received two doses of Takeda's TDV in the parent trials with no new major protocol violations in this trial prior to administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"unitless ratio","timeFrame":"Month 12 vs Month 0, Month 15 (DEN-304) vs parent trial Month 4, Month 42 (DEN315) vs parent trial Month 4, Month 0 vs parent trial Month 9, Month 12 vs parent trial Month 9","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"119"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Month 12 vs Month 0: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.736","lowerLimit":"0.556","upperLimit":"0.974"},{"groupId":"OG001","value":"0.705","lowerLimit":"0.002","upperLimit":"222.445"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 12 vs Month 0: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.756","lowerLimit":"0.599","upperLimit":"0.955"},{"groupId":"OG001","value":"0.456","lowerLimit":"0.056","upperLimit":"3.733"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 12 vs Month 0: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.980","lowerLimit":"0.834","upperLimit":"1.152"},{"groupId":"OG001","value":"1.000","lowerLimit":"NA","upperLimit":"NA","comment":"The confidence interval was not estimable due to an observed standard deviation of 0."}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 12 vs Month 0: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.736","lowerLimit":"0.598","upperLimit":"0.906"},{"groupId":"OG001","value":"0.727","lowerLimit":"0.064","upperLimit":"8.280"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 15 (DEN-304) vs Parent Trial Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.506","lowerLimit":"0.349","upperLimit":"0.733"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 15 (DEN-304) vs Parent Trial Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.164","lowerLimit":"0.108","upperLimit":"0.249"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 15 (DEN-304) vs Parent Trial Month 4: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.350","lowerLimit":"0.238","upperLimit":"0.514"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 15 (DEN-304) vs Parent Trial Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.221","lowerLimit":"0.150","upperLimit":"0.327"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 42 (DEN-315) vs Parent Trial Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.393","lowerLimit":"0.155","upperLimit":"0.998"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 42 (DEN-315) vs Parent Trial Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.164","lowerLimit":"0.066","upperLimit":"0.408"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 42 (DEN-315) vs Parent Trial Month 4: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.319","lowerLimit":"0.204","upperLimit":"0.499"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 42 (DEN-315) vs Parent Trial Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.104","lowerLimit":"0.042","upperLimit":"0.258"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 0 vs Parent Trial Month 9: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.635","lowerLimit":"0.467","upperLimit":"0.864"},{"groupId":"OG001","value":"0.528","lowerLimit":"0.453","upperLimit":"0.616"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 0 vs Parent Trial Month 9: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.469","lowerLimit":"0.356","upperLimit":"0.619"},{"groupId":"OG001","value":"0.454","lowerLimit":"0.312","upperLimit":"0.661"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 0 vs Parent Trial Month 9: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.538","lowerLimit":"0.361","upperLimit":"0.801"},{"groupId":"OG001","value":"0.556","lowerLimit":"0.356","upperLimit":"0.868"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 0 vs Parent Trial Month 9: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.710","lowerLimit":"0.475","upperLimit":"1.062"},{"groupId":"OG001","value":"0.684","lowerLimit":"0.401","upperLimit":"1.165"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 12 vs Parent Trial Month 9: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.497","lowerLimit":"0.330","upperLimit":"0.748"},{"groupId":"OG001","value":"0.375","lowerLimit":"0.000","upperLimit":"400.159"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 12 vs Parent Trial Month 9: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.311","lowerLimit":"0.203","upperLimit":"0.477"},{"groupId":"OG001","value":"0.172","lowerLimit":"0.161","upperLimit":"0.184"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 12 vs Parent Trial Month 9: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.561","lowerLimit":"0.329","upperLimit":"0.957"},{"groupId":"OG001","value":"0.664","lowerLimit":"0.004","upperLimit":"119.652"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Month 12 vs Parent Trial Month 9: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.577","lowerLimit":"0.335","upperLimit":"0.994"},{"groupId":"OG001","value":"0.966","lowerLimit":"0.005","upperLimit":"194.455"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 12 vs Month 0; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.756","lowerLimit":"0.671","upperLimit":"0.851"},{"groupId":"OG001","value":"0.900","lowerLimit":"0.745","upperLimit":"1.088"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 12 vs Month 0; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.689","lowerLimit":"0.639","upperLimit":"0.742"},{"groupId":"OG001","value":"0.630","lowerLimit":"0.553","upperLimit":"0.718"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 12 vs Month 0; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.847","lowerLimit":"0.767","upperLimit":"0.936"},{"groupId":"OG001","value":"0.846","lowerLimit":"0.656","upperLimit":"1.092"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 12 vs Month 0; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.684","lowerLimit":"0.622","upperLimit":"0.753"},{"groupId":"OG001","value":"0.867","lowerLimit":"0.708","upperLimit":"1.063"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 15 (DEN-304) vs Parent Trial Month 4; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.427","lowerLimit":"0.368","upperLimit":"0.496"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 15 (DEN-304) vs Parent Trial Month 4; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.158","lowerLimit":"0.135","upperLimit":"0.186"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 15 (DEN-304) vs Parent Trial Month 4; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.265","lowerLimit":"0.229","upperLimit":"0.305"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 15 (DEN-304) vs Parent Trial Month 4; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.241","lowerLimit":"0.200","upperLimit":"0.290"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 42 (DEN-315) vs Parent Trial Month 4; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.288","lowerLimit":"0.231","upperLimit":"0.359"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 42 (DEN-315) vs Parent Trial Month 4; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.103","lowerLimit":"0.085","upperLimit":"0.125"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 42 (DEN-315) vs Parent Trial Month 4; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.192","lowerLimit":"0.152","upperLimit":"0.244"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 42 (DEN-315) vs Parent Trial Month 4; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.094","lowerLimit":"0.075","upperLimit":"0.118"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 0 vs Parent Trial Month 9; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.514","lowerLimit":"0.466","upperLimit":"0.567"},{"groupId":"OG001","value":"0.516","lowerLimit":"0.450","upperLimit":"0.592"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 0 vs Parent Trial Month 9; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.385","lowerLimit":"0.359","upperLimit":"0.414"},{"groupId":"OG001","value":"0.467","lowerLimit":"0.413","upperLimit":"0.527"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 0 vs Parent Trial Month 9; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.426","lowerLimit":"0.381","upperLimit":"0.477"},{"groupId":"OG001","value":"0.547","lowerLimit":"0.472","upperLimit":"0.633"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 0 vs Parent Trial Month 9; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.557","lowerLimit":"0.501","upperLimit":"0.619"},{"groupId":"OG001","value":"0.560","lowerLimit":"0.494","upperLimit":"0.634"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 12 vs Parent Trial Month 9; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.403","lowerLimit":"0.354","upperLimit":"0.459"},{"groupId":"OG001","value":"0.492","lowerLimit":"0.378","upperLimit":"0.641"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 12 vs Parent Trial Month 9; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.259","lowerLimit":"0.233","upperLimit":"0.287"},{"groupId":"OG001","value":"0.296","lowerLimit":"0.242","upperLimit":"0.362"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 12 vs Parent Trial Month 9; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.387","lowerLimit":"0.335","upperLimit":"0.446"},{"groupId":"OG001","value":"0.426","lowerLimit":"0.327","upperLimit":"0.556"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Month 12 vs Parent Trial Month 9; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.361","lowerLimit":"0.316","upperLimit":"0.412"},{"groupId":"OG001","value":"0.553","lowerLimit":"0.416","upperLimit":"0.734"}]}]}]},{"type":"SECONDARY","title":"GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Booster Phase","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"unitless ratio","timeFrame":"Months (M) 1&6 post-booster dose in current trial vs M 4 in parent trials; post-booster M 6 vs post-booster M 1; post-booster M 1 vs pre-booster (M 15 for DEN-304/M 42 for DEN-315); post-booster M 6 vs pre-booster (M 15 for DEN-304/M 42 for DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"100"}]}],"classes":[{"title":"Booster Month 1 vs Parent Trial Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"94"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.352","lowerLimit":"0.296","upperLimit":"0.417"},{"groupId":"OG001","value":"4.298","lowerLimit":"3.204","upperLimit":"5.767"}]}]},{"title":"Booster Month 1 vs Parent Trial Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"94"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.124","lowerLimit":"0.107","upperLimit":"0.144"},{"groupId":"OG001","value":"0.378","lowerLimit":"0.285","upperLimit":"0.502"}]}]},{"title":"Booster Month 1 vs Parent Trial Month 4: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"94"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.231","lowerLimit":"0.188","upperLimit":"0.284"},{"groupId":"OG001","value":"3.042","lowerLimit":"2.217","upperLimit":"4.175"}]}]},{"title":"Booster Month 1 vs Parent Trial Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"94"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.162","lowerLimit":"0.127","upperLimit":"0.206"},{"groupId":"OG001","value":"1.966","lowerLimit":"1.412","upperLimit":"2.738"}]}]},{"title":"Booster Month 6 vs Parent Trial Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.285","lowerLimit":"0.235","upperLimit":"0.345"},{"groupId":"OG001","value":"1.409","lowerLimit":"1.036","upperLimit":"1.917"}]}]},{"title":"Booster Month 6 vs Parent Trial Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.100","lowerLimit":"0.086","upperLimit":"0.117"},{"groupId":"OG001","value":"0.206","lowerLimit":"0.158","upperLimit":"0.269"}]}]},{"title":"Booster Month 6 vs Parent Trial Month 4:DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.225","lowerLimit":"0.187","upperLimit":"0.272"},{"groupId":"OG001","value":"1.133","lowerLimit":"0.816","upperLimit":"1.573"}]}]},{"title":"Booster Month 6 vs Parent Trial Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.136","lowerLimit":"0.110","upperLimit":"0.169"},{"groupId":"OG001","value":"0.609","lowerLimit":"0.445","upperLimit":"0.834"}]}]},{"title":"Booster Month 6 vs Booster Month 1: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.817","lowerLimit":"0.730","upperLimit":"0.914"},{"groupId":"OG001","value":"0.334","lowerLimit":"0.283","upperLimit":"0.395"}]}]},{"title":"Booster Month 6 vs Booster Month 1: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.825","lowerLimit":"0.753","upperLimit":"0.903"},{"groupId":"OG001","value":"0.535","lowerLimit":"0.452","upperLimit":"0.634"}]}]},{"title":"Booster Month 6 vs Booster Month 1: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.990","lowerLimit":"0.894","upperLimit":"1.096"},{"groupId":"OG001","value":"0.370","lowerLimit":"0.295","upperLimit":"0.463"}]}]},{"title":"Booster Month 6 vs Booster Month 1: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.875","lowerLimit":"0.746","upperLimit":"1.026"},{"groupId":"OG001","value":"0.317","lowerLimit":"0.255","upperLimit":"0.394"}]}]},{"title":"Booster Month 1 vs Pre-booster dose: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.962","lowerLimit":"0.879","upperLimit":"1.053"},{"groupId":"OG001","value":"11.762","lowerLimit":"8.660","upperLimit":"15.975"}]}]},{"title":"Booster Month 1 vs Pre-booster dose: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.936","lowerLimit":"0.862","upperLimit":"1.016"},{"groupId":"OG001","value":"2.822","lowerLimit":"2.208","upperLimit":"3.607"}]}]},{"title":"Booster Month 1 vs Pre-booster dose: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.856","lowerLimit":"0.773","upperLimit":"0.948"},{"groupId":"OG001","value":"14.889","lowerLimit":"10.992","upperLimit":"20.170"}]}]},{"title":"Booster Month 1 vs Pre-booster dose: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.960","lowerLimit":"0.816","upperLimit":"1.130"},{"groupId":"OG001","value":"13.890","lowerLimit":"9.549","upperLimit":"20.204"}]}]},{"title":"Booster Month 6 vs Pre-booster dose: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.784","lowerLimit":"0.699","upperLimit":"0.879"},{"groupId":"OG001","value":"3.810","lowerLimit":"2.847","upperLimit":"5.097"}]}]},{"title":"Booster Month 6 vs Pre-booster dose: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.763","lowerLimit":"0.697","upperLimit":"0.835"},{"groupId":"OG001","value":"1.550","lowerLimit":"1.250","upperLimit":"1.923"}]}]},{"title":"Booster Month 6 vs Pre-booster dose: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.858","lowerLimit":"0.767","upperLimit":"0.960"},{"groupId":"OG001","value":"5.622","lowerLimit":"4.151","upperLimit":"7.614"}]}]},{"title":"Booster Month 6 vs Pre-booster dose: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.834","lowerLimit":"0.708","upperLimit":"0.983"},{"groupId":"OG001","value":"4.412","lowerLimit":"3.187","upperLimit":"6.108"}]}]}]},{"type":"SECONDARY","title":"GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes by Serostatus at Baseline in the Parent Trials in the Booster Phase","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial.","populationDescription":"PPS-B included all participants from the FAS-B who received two doses of Takeda's TDV in the parent trials with no new major protocol violations after administration of the trial vaccination at Visit 3 that could potentially confound the primary endpoints in the current trial. Number analyzed: number of participants with data available for analysis for the specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"unitless ratio","timeFrame":"Months (M) 1&6 post-booster dose in current trial vs M 4 in parent trials; post-booster M 1 vs pre-booster (M 15 for DEN-304/M 42 for DEN-315); post-booster M 6 vs pre-booster (M 15 for DEN-304/M 42 for DEN-315); post-booster M 6 vs post-booster M 1","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"100"}]}],"classes":[{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 1 vs Parent Trial Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.413","lowerLimit":"0.236","upperLimit":"0.721"},{"groupId":"OG001","value":"2.219","lowerLimit":"1.181","upperLimit":"4.169"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 1 vs Parent Trial Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.118","lowerLimit":"0.077","upperLimit":"0.180"},{"groupId":"OG001","value":"0.355","lowerLimit":"0.203","upperLimit":"0.620"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 1 vs Parent Trial Month 4: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.311","lowerLimit":"0.186","upperLimit":"0.520"},{"groupId":"OG001","value":"1.566","lowerLimit":"0.684","upperLimit":"3.583"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 1 vs Parent Trial Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.229","lowerLimit":"0.144","upperLimit":"0.363"},{"groupId":"OG001","value":"1.215","lowerLimit":"0.662","upperLimit":"2.231"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 1 vs Pre-booster dose: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.033","lowerLimit":"0.833","upperLimit":"1.280"},{"groupId":"OG001","value":"3.683","lowerLimit":"1.612","upperLimit":"8.412"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 1 vs Pre-booster dose: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.803","lowerLimit":"0.615","upperLimit":"1.049"},{"groupId":"OG001","value":"1.805","lowerLimit":"1.311","upperLimit":"2.485"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 1 vs Pre-booster dose: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.825","lowerLimit":"0.580","upperLimit":"1.174"},{"groupId":"OG001","value":"3.699","lowerLimit":"1.738","upperLimit":"7.873"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 1 vs Pre-booster dose: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.203","lowerLimit":"0.681","upperLimit":"2.126"},{"groupId":"OG001","value":"5.237","lowerLimit":"1.977","upperLimit":"13.872"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Pre-booster dose: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.065","lowerLimit":"0.673","upperLimit":"1.686"},{"groupId":"OG001","value":"1.404","lowerLimit":"0.787","upperLimit":"2.506"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Pre-booster dose: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.739","lowerLimit":"0.480","upperLimit":"1.137"},{"groupId":"OG001","value":"0.906","lowerLimit":"0.673","upperLimit":"1.221"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Pre-booster dose: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.965","lowerLimit":"0.733","upperLimit":"1.271"},{"groupId":"OG001","value":"1.544","lowerLimit":"0.868","upperLimit":"2.748"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Pre-booster dose: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.903","lowerLimit":"0.513","upperLimit":"1.588"},{"groupId":"OG001","value":"1.635","lowerLimit":"0.724","upperLimit":"3.690"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Booster Month 1: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.998","lowerLimit":"0.742","upperLimit":"1.343"},{"groupId":"OG001","value":"0.379","lowerLimit":"0.221","upperLimit":"0.650"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Booster Month 1: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.026","lowerLimit":"0.713","upperLimit":"1.475"},{"groupId":"OG001","value":"0.506","lowerLimit":"0.330","upperLimit":"0.775"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Booster Month 1: DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.024","lowerLimit":"0.821","upperLimit":"1.278"},{"groupId":"OG001","value":"0.437","lowerLimit":"0.255","upperLimit":"0.750"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Booster Month 1: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.837","lowerLimit":"0.492","upperLimit":"1.425"},{"groupId":"OG001","value":"0.329","lowerLimit":"0.173","upperLimit":"0.624"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Parent Trial Month 4: DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.400","lowerLimit":"0.175","upperLimit":"0.915"},{"groupId":"OG001","value":"0.779","lowerLimit":"0.379","upperLimit":"1.599"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Parent Trial Month 4: DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.103","lowerLimit":"0.066","upperLimit":"0.162"},{"groupId":"OG001","value":"0.161","lowerLimit":"0.086","upperLimit":"0.304"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Parent Trial Month 4:DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.333","lowerLimit":"0.215","upperLimit":"0.515"},{"groupId":"OG001","value":"0.593","lowerLimit":"0.267","upperLimit":"1.321"}]}]},{"title":"Parent Trial Baseline Serostatus: Positive; Booster Month 6 vs Parent Trial Month 4: DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.113","lowerLimit":"0.063","upperLimit":"0.201"},{"groupId":"OG001","value":"0.314","lowerLimit":"0.134","upperLimit":"0.735"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 1 vs Parent Trial Month 4; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.343","lowerLimit":"0.286","upperLimit":"0.413"},{"groupId":"OG001","value":"4.692","lowerLimit":"3.404","upperLimit":"6.467"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 1 vs Parent Trial Month 4; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.125","lowerLimit":"0.106","upperLimit":"0.147"},{"groupId":"OG001","value":"0.382","lowerLimit":"0.278","upperLimit":"0.523"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 1 vs Parent Trial Month 4; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.221","lowerLimit":"0.177","upperLimit":"0.277"},{"groupId":"OG001","value":"3.322","lowerLimit":"2.359","upperLimit":"4.678"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 1 vs Parent Trial Month 4; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.130","lowerLimit":"0.099","upperLimit":"0.171"},{"groupId":"OG001","value":"1.585","lowerLimit":"1.112","upperLimit":"2.259"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 1 vs Pre-booster dose; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.953","lowerLimit":"0.862","upperLimit":"1.053"},{"groupId":"OG001","value":"13.646","lowerLimit":"9.906","upperLimit":"18.796"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 1 vs Pre-booster dose; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.956","lowerLimit":"0.876","upperLimit":"1.043"},{"groupId":"OG001","value":"2.988","lowerLimit":"2.275","upperLimit":"3.925"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 1 vs Pre-booster dose; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.860","lowerLimit":"0.771","upperLimit":"0.959"},{"groupId":"OG001","value":"17.792","lowerLimit":"13.012","upperLimit":"24.329"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 1 vs Pre-booster dose; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.939","lowerLimit":"0.820","upperLimit":"1.074"},{"groupId":"OG001","value":"14.586","lowerLimit":"10.186","upperLimit":"20.888"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Pre-booster dose; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.756","lowerLimit":"0.672","upperLimit":"0.851"},{"groupId":"OG001","value":"4.425","lowerLimit":"3.233","upperLimit":"6.056"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Pre-booster dose; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.766","lowerLimit":"0.698","upperLimit":"0.840"},{"groupId":"OG001","value":"1.680","lowerLimit":"1.321","upperLimit":"2.137"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Pre-booster dose; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.846","lowerLimit":"0.749","upperLimit":"0.957"},{"groupId":"OG001","value":"6.824","lowerLimit":"4.957","upperLimit":"9.395"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Pre-booster dose; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.801","lowerLimit":"0.692","upperLimit":"0.926"},{"groupId":"OG001","value":"4.837","lowerLimit":"3.533","upperLimit":"6.623"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Booster Month 1; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.799","lowerLimit":"0.709","upperLimit":"0.902"},{"groupId":"OG001","value":"0.328","lowerLimit":"0.274","upperLimit":"0.393"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Booster Month 1; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.805","lowerLimit":"0.733","upperLimit":"0.885"},{"groupId":"OG001","value":"0.539","lowerLimit":"0.447","upperLimit":"0.650"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Booster Month 1; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.986","lowerLimit":"0.882","upperLimit":"1.103"},{"groupId":"OG001","value":"0.361","lowerLimit":"0.282","upperLimit":"0.463"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Booster Month 1; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.850","lowerLimit":"0.746","upperLimit":"0.969"},{"groupId":"OG001","value":"0.319","lowerLimit":"0.255","upperLimit":"0.399"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Parent Trial Month 4; DENV-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.273","lowerLimit":"0.224","upperLimit":"0.333"},{"groupId":"OG001","value":"1.546","lowerLimit":"1.102","upperLimit":"2.168"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Parent Trial Month 4; DENV-2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.100","lowerLimit":"0.085","upperLimit":"0.118"},{"groupId":"OG001","value":"0.214","lowerLimit":"0.160","upperLimit":"0.288"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Parent Trial Month 4; DENV-3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.215","lowerLimit":"0.175","upperLimit":"0.263"},{"groupId":"OG001","value":"1.253","lowerLimit":"0.875","upperLimit":"1.795"}]}]},{"title":"Parent Trial Baseline Serostatus: Negative; Booster Month 6 vs Parent Trial Month 4; DENV-4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.109","lowerLimit":"0.086","upperLimit":"0.139"},{"groupId":"OG001","value":"0.498","lowerLimit":"0.357","upperLimit":"0.694"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Within 7 Days Post-Booster Vaccination","description":"Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days post-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315). AEs were graded by the investigator in the following manner: Mild: Grade 1: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with everyday activities. Relieved with or without symptomatic treatment; Moderate: Grade 2: Sufficient discomfort is present to cause interference with normal activity. Only partially relieved with symptomatic treatment; Severe: Grade 3: Extreme distress, causing significant impairment of functioning or incapacitation. Prevents normal everyday activities. Not relieved with symptomatic treatment.","populationDescription":"Safety Set-Booster (SAF-B) included all participants who received at least one dose of Takeda's TDV in the parent trials and who received the trial vaccination in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 1 through 7 post-booster dose at Visit 3 (Month 15 [DEN-304]) and (Month 42 [DEN-315])","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"112"}]}],"classes":[{"title":"Mild","categories":[{"measurements":[{"groupId":"OG000","value":"17.4"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.2"},{"groupId":"OG001","value":"14.3"}]}]},{"title":"Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Systemic Adverse Events Within 14 Days Post-Booster Vaccination by Severity","description":"Solicited systemic AEs are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days post-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315). AEs were graded by the investigator in the following manner: Mild: Grade 1: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with everyday activities. Relieved with or without symptomatic treatment; Moderate: Grade 2: Sufficient discomfort is present to cause interference with normal activity. Only partially relieved with symptomatic treatment; Severe: Grade 3: Extreme distress, causing significant impairment of functioning or incapacitation. Prevents normal everyday activities. Not relieved with symptomatic treatment.","populationDescription":"SAF-B included all participants who received at least one dose of Takeda's TDV in the parent trials and who received the trial vaccination in the current trial. Overall number of participants analyzed: number of participants with data available for analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 1 through 14 post-booster dose at Visit 3 (Month 15 [DEN-304]) and (Month 42 [DEN-315])","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"112"}]}],"classes":[{"title":"Mild","categories":[{"measurements":[{"groupId":"OG000","value":"30.4"},{"groupId":"OG001","value":"32.1"}]}]},{"title":"Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"12.2"},{"groupId":"OG001","value":"17.0"}]}]},{"title":"Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"3.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Unsolicited AEs in the Booster Phase","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine or placebo; it does not necessarily have to have a causal relationship with this treatment.","populationDescription":"SAF-B included all participants who received at least one dose of Takeda's TDV in the parent trials and who received the trial vaccination in the current trial.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 1 through 28 post-booster dose at Visit 3 (Month 15 [DEN-304]) and (Month 42 [DEN-315])","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"115"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8"},{"groupId":"OG001","value":"6.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Medically Attended AEs (MAAEs) in the Booster Phase","description":"MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.","populationDescription":"SAF-B included all participants who received at least one dose of Takeda's TDV in the parent trials and who received the trial vaccination in the current trial.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Month 15 post-booster dose through Month 21 (DEN-304); Month 42 post-booster dose through Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"115"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9"},{"groupId":"OG001","value":"11.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Serious Adverse Events (SAEs) Prior to the Booster Dose","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine or placebo; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important event.","populationDescription":"SAF included all participants who agreed to participate in the current trial, did not screen fail, and who received at least one dose of Takeda's TDV in the parent trials.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Month 0 through Month 15 (DEN-304) and Month 42 (DEN-315)","groups":[{"id":"OG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15)."},{"id":"OG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"6.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any SAEs in the Booster Phase","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine or placebo; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important event.","populationDescription":"SAF-B included all participants who received at least one dose of Takeda's TDV in the parent trials and who received the trial vaccination in the current trial.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Month 15 post-booster dose after vaccination through Month 21 (DEN-304); Month 42 post-booster dose after vaccination through Month 48 (DEN-315)","groups":[{"id":"OG000","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 ml injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."},{"id":"OG001","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 ml, injection, SC, once at Visit 3 (Month 15) for participants from parent trial DEN-304 (US) or once at Visit 3 (Month 42) for participants from parent trial DEN-315 (Mexico)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"115"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"All-cause mortality & SAEs: From Day 1 [Month 0] up to Month 21 (DEN-304) & Month 48 (DEN-315); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Months 15 (DEN-304) & 42 (DEN-315).","description":"Prior to Booster Arms: SAF included all participants who agreed to participate in current trial,did not screen fail\\& who received at least 1 dose of Takeda's TDV in parent trials.\n\nBooster Phase Arms: SAF-B included all participants who received at least 1 dose of Takeda's TDV in parent trials \\&who received the trial vaccination in current trial.","eventGroups":[{"id":"EG000","title":"Prior to Booster: DEN-304","description":"Participants who received TDV in parent trial DEN-304 (US) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 15).","deathsNumAffected":0,"deathsNumAtRisk":246,"seriousNumAffected":6,"seriousNumAtRisk":246,"otherNumAffected":0,"otherNumAtRisk":246},{"id":"EG001","title":"Prior to Booster: DEN-315","description":"Participants who received TDV in parent trial DEN-315 (Mexico) were assessed before they received booster dose (Placebo/TDV) at Visit 3 (Month 42).","deathsNumAffected":1,"deathsNumAtRisk":119,"seriousNumAffected":8,"seriousNumAtRisk":119,"otherNumAffected":0,"otherNumAtRisk":119},{"id":"EG002","title":"Booster Phase: TDV","description":"Participants received TDV 0.5 mL, injection, subcutaneously, once at Month 15 for participants from parent trials DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).","deathsNumAffected":0,"deathsNumAtRisk":115,"seriousNumAffected":0,"seriousNumAtRisk":115,"otherNumAffected":83,"otherNumAtRisk":115},{"id":"EG003","title":"Booster Phase: Placebo","description":"Participants received TDV placebo-matching 0.5 mL injection, subcutaneously, once at Month 15 for participants from parent trial DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).","deathsNumAffected":0,"deathsNumAtRisk":118,"seriousNumAffected":3,"seriousNumAtRisk":118,"otherNumAffected":57,"otherNumAtRisk":118}],"seriousEvents":[{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":1,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":1,"numAtRisk":118}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":1,"numAtRisk":118}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":246},{"groupId":"EG001","numAffected":1,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":1,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":1,"numAtRisk":118}]},{"term":"Intervertebral disc degeneration","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":1,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Mastitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":1,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Pilonidal disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":1,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":1,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":1,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Uterine atony","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":2,"numAtRisk":119},{"groupId":"EG002","numAffected":0,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]}],"otherEvents":[{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":28,"numAtRisk":115},{"groupId":"EG003","numAffected":22,"numAtRisk":118}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":29,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":42,"numAtRisk":115},{"groupId":"EG003","numAffected":38,"numAtRisk":118}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":8,"numAtRisk":115},{"groupId":"EG003","numAffected":2,"numAtRisk":118}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":28,"numAtRisk":115},{"groupId":"EG003","numAffected":23,"numAtRisk":118}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":40,"numAtRisk":115},{"groupId":"EG003","numAffected":22,"numAtRisk":118}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":70,"numAtRisk":115},{"groupId":"EG003","numAffected":26,"numAtRisk":118}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":16,"numAtRisk":115},{"groupId":"EG003","numAffected":0,"numAtRisk":118}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":246},{"groupId":"EG001","numAffected":0,"numAtRisk":119},{"groupId":"EG002","numAffected":5,"numAtRisk":115},{"groupId":"EG003","numAffected":6,"numAtRisk":118}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Study Director","organization":"Takeda","email":"TrialDisclosures@takeda.com","phone":"+1-877-825-3327"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-08-22","uploadDate":"2025-05-23T08:27","filename":"Prot_000.pdf","size":24573942},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-09-13","uploadDate":"2025-05-23T08:28","filename":"SAP_001.pdf","size":1188872}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D003715","term":"Dengue"}],"ancestors":[{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D007239","term":"Infections"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018177","term":"Flavivirus Infections"},{"id":"D018178","term":"Flaviviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D006482","term":"Hemorrhagic Fevers, Viral"}]}},"hasResults":true}